1
|
Garciaz S, de Nonneville A, Maraninchi D. [Cancer: The need to believe]. Bull Cancer 2024:S0007-4551(24)00129-2. [PMID: 38714464 DOI: 10.1016/j.bulcan.2024.04.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2024] [Accepted: 04/17/2024] [Indexed: 05/09/2024]
Affiliation(s)
- Sylvain Garciaz
- Institut Paoli-Calmettes, CRCM, Aix-Marseille université, CNRS, Inserm, Marseille, France
| | | | - Dominique Maraninchi
- Institut Paoli-Calmettes, CRCM, Aix-Marseille université, CNRS, Inserm, Marseille, France.
| |
Collapse
|
2
|
Garciaz S, Berton G, Hospital MA, Guille A, Adélaïde J, Saillard C, Hicheri Y, Mozziconacci MJ, Duprez E, Récher C, Alary AS, Birnbaum D, Vey N. Long-term survival of NPM1 AML treated with intensive chemotherapy with extensive molecular data available. Leuk Lymphoma 2024; 65:700-703. [PMID: 38329727 DOI: 10.1080/10428194.2024.2312430] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2023] [Accepted: 01/26/2024] [Indexed: 02/09/2024]
Affiliation(s)
- Sylvain Garciaz
- Department of Hematology, Institut Paoli-Calmettes, INSERM UMR 1068, CNRS UMR725, CNRS, Aix-Marseille University, Marseille, France
| | - Guillaume Berton
- Department of Hematology, Institut Paoli-Calmettes, INSERM UMR 1068, CNRS UMR725, CNRS, Aix-Marseille University, Marseille, France
| | - Marie-Anne Hospital
- Department of Hematology, Institut Paoli-Calmettes, INSERM UMR 1068, CNRS UMR725, CNRS, Aix-Marseille University, Marseille, France
| | - Arnaud Guille
- Predictive Oncology Laboratory, Marseille Cancer Research Center, INSERMUMR 1068, CNRS UMR725, CNRS, Aix-Marseille University, Marseille, France
| | - José Adélaïde
- Predictive Oncology Laboratory, Marseille Cancer Research Center, INSERMUMR 1068, CNRS UMR725, CNRS, Aix-Marseille University, Marseille, France
| | - Colombe Saillard
- Department of Hematology, Institut Paoli-Calmettes, INSERM UMR 1068, CNRS UMR725, CNRS, Aix-Marseille University, Marseille, France
| | - Yosr Hicheri
- Department of Hematology, Institut Paoli-Calmettes, INSERM UMR 1068, CNRS UMR725, CNRS, Aix-Marseille University, Marseille, France
| | | | - Estelle Duprez
- Epigenetic Factors in Normal and Malignant Hematopoiesis, Marseille Cancer Research Center, INSERMUMR 1068, CNRS UMR725, CNRS, Aix-Marseille University, Marseille, France
| | - Christian Récher
- Department of Hematology, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
- Université Toulouse III Paul Sabatier, Cancer Research Center of Toulouse, UMR1037-INSERM, ERL5294 CNRS, Toulouse, France
| | - Anne-Sophie Alary
- Department of Cancer Biology, Institut Paoli-Calmettes, Marseille, France
| | - Daniel Birnbaum
- Predictive Oncology Laboratory, Marseille Cancer Research Center, INSERMUMR 1068, CNRS UMR725, CNRS, Aix-Marseille University, Marseille, France
| | - Norbert Vey
- Department of Hematology, Institut Paoli-Calmettes, INSERM UMR 1068, CNRS UMR725, CNRS, Aix-Marseille University, Marseille, France
| |
Collapse
|
3
|
Berton G, Sedaki B, Collomb E, Benachour S, Loschi M, Mohty B, Saillard C, Hicheri Y, Rouzaud C, Maisano V, Villetard F, Corda ED'I, Charbonnier A, Rey J, Hospital MA, Ittel A, Abbou N, Fanciullino R, Dadone-Montaudié B, Vey N, Venton G, Cluzeau T, Alary AS, Garciaz S. Poor prognosis of SRSF2 gene mutations in patients treated with VEN-AZA for newly diagnosed acute myeloid leukemia. Leuk Res 2024; 141:107500. [PMID: 38636413 DOI: 10.1016/j.leukres.2024.107500] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2024] [Revised: 04/04/2024] [Accepted: 04/08/2024] [Indexed: 04/20/2024]
Abstract
Mutations in spliceosome genes (SRSF2, SF3B1, U2AF1, ZRSR2) correlate with inferior outcomes in patients treated with intensive chemotherapy for Acute Myeloid Leukemia. However, their prognostic impact in patients treated with less intensive protocols is not well known. This study aimed to evaluate the impact of Spliceosome mutations in patients treated with Venetoclax and Azacitidine for newly diagnosed AML. 117 patients treated in 3 different hospitals were included in the analysis. 34 harbored a mutation in at least one of the spliceosome genes (splice-mut cohort). K/NRAS mutations were more frequent in the splice-mut cohort (47% vs 19%, p=0.0022). Response rates did not differ between splice-mut and splice-wt cohorts. With a median follow-up of 15 months, splice mutations were associated with a lower 18-month LFS (p=0.0045). When analyzing splice mutations separately, we found SRSF2 mutations to be associated with poorer outcomes (p=0.034 and p=0.037 for OS and LFS respectively). This negative prognostic impact remained true in our multivariate analysis. We believe this finding should warrant further studies aimed at overcoming this negative impact.
Collapse
Affiliation(s)
- Guillaume Berton
- Department of Hematology, Institut Paoli-Calmettes, Marseille, France.
| | - Bochra Sedaki
- Department of Hematology, University Hospital Centre L'Archet, Nice, France
| | - Erwann Collomb
- Department of Hematology and Cellular Therapy, La Conception Hospital, Marseille, France
| | - Sami Benachour
- Department of Hematology, University Hospital Centre L'Archet, Nice, France
| | - Michael Loschi
- Department of Hematology, University Hospital Centre L'Archet, Nice, France
| | - Bilal Mohty
- Department of Hematology, Institut Paoli-Calmettes, Marseille, France
| | - Colombe Saillard
- Department of Hematology, Institut Paoli-Calmettes, Marseille, France
| | - Yosr Hicheri
- Department of Hematology, Institut Paoli-Calmettes, Marseille, France
| | - Camille Rouzaud
- Department of Hematology, Institut Paoli-Calmettes, Marseille, France
| | - Valerio Maisano
- Department of Hematology, Institut Paoli-Calmettes, Marseille, France
| | | | | | - Aude Charbonnier
- Department of Hematology, Institut Paoli-Calmettes, Marseille, France
| | - Jerome Rey
- Department of Hematology, Institut Paoli-Calmettes, Marseille, France
| | - Marie-Anne Hospital
- Department of Hematology, Institut Paoli-Calmettes, Marseille, France; Aix-Marseille University, INSERM U1068, CNRS, Institut Paoli-Calmettes, CRCM, Marseille, France
| | - Antoine Ittel
- Department of Molecular Biology, Institut Paoli-Calmettes, Marseille, France
| | - Norman Abbou
- Department of Molecular Biology, Hôpital Nord, Marseille, France
| | - Raphaelle Fanciullino
- SMARTc: Simulation and Modeling: Adaptative Response for Therapeutics in Cancer, Marseille, France; Faculté de Pharmacie de Marseille, CRCM Inserm UMR, Marseille 1068, France; Pharmacy, Hôpital de la Conception, Marseille, France
| | | | - Norbert Vey
- Department of Hematology, Institut Paoli-Calmettes, Marseille, France; Aix-Marseille University, INSERM U1068, CNRS, Institut Paoli-Calmettes, CRCM, Marseille, France
| | - Geoffroy Venton
- Department of Hematology and Cellular Therapy, La Conception Hospital, Marseille, France
| | - Thomas Cluzeau
- Department of Hematology, University Hospital Centre L'Archet, Nice, France; INSERMU1065, C3M / Cote d'Azur University; Nice, France
| | - Anne-Sophie Alary
- Department of Molecular Biology, Institut Paoli-Calmettes, Marseille, France
| | - Sylvain Garciaz
- Department of Hematology, Institut Paoli-Calmettes, Marseille, France; Aix-Marseille University, INSERM U1068, CNRS, Institut Paoli-Calmettes, CRCM, Marseille, France
| |
Collapse
|
4
|
Petit C, Saillard C, Mohty B, Hicheri Y, Villetard F, Maisano V, Charbonnier A, Rey J, D'Incan E, Rouzaud C, Gelsi-Boyer V, Murati A, Lhoumeau AC, Ittel A, Mozziconacci MJ, Alary AS, Hospital MA, Vey N, Garciaz S. Azacitidine-venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients. Eur J Haematol 2024; 112:530-537. [PMID: 38031389 DOI: 10.1111/ejh.14140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2023] [Revised: 11/09/2023] [Accepted: 11/10/2023] [Indexed: 12/01/2023]
Abstract
OBJECTIVES To compare the efficacy of venetoclax-azacitidine (VEN-AZA) with AZA in the real-life for patients with first relapsed or refractory acute myeloid leukaemia (R/R AML). METHODS We retrospectively analysed R/R AML patients treated with VEN-AZA at the Institut Paoli Calmettes between September 2020 and February 2022. We compared them to a historical cohort of patients treated with AZA between 2010 and 2021. RESULTS Thirty-five patients treated with VEN-AZA were compared with 140 patients treated with AZA. There were more favourable cytogenetics (25.7% vs. 8.6%; p = 0.01) and less FLT3-ITD mutated AML (8.8% vs. 25.5%; p = .049) in the VEN-AZA group. The overall 30-day mortality rate was 7.4% and the overall 90-day mortality was 20%, with no difference between the groups. The complete remission rate was 48.6% in the VEN-AZA group versus 15% (p < .0001). The composite complete response rate was 65.7% in the VEN-AZA group versus 23.6% (p < .0001). OS was 12.8 months in the VEN-AZA group versus 7.3 months (p = 0.059). Patients with primary refractory AML, poor-risk cytogenetics, prior hematopoietic stem-cell transplantation (HSCT) and FLT3-ITD mutated AML had lower response and survival rates. CONCLUSION VEN-AZA was associated with a better response rate and a longer survival than AZA monotherapy in AML patients who relapsed after or were refractory to intensive chemotherapy.
Collapse
Affiliation(s)
- C Petit
- Département d'hématologie, Institut Paoli-Calmettes, Marseille, France
| | - C Saillard
- Département d'hématologie, Institut Paoli-Calmettes, Marseille, France
| | - B Mohty
- Département d'hématologie, Institut Paoli-Calmettes, Marseille, France
| | - Y Hicheri
- Département d'hématologie, Institut Paoli-Calmettes, Marseille, France
| | - F Villetard
- Département d'hématologie, Institut Paoli-Calmettes, Marseille, France
| | - V Maisano
- Département d'hématologie, Institut Paoli-Calmettes, Marseille, France
| | - A Charbonnier
- Département d'hématologie, Institut Paoli-Calmettes, Marseille, France
| | - J Rey
- Département d'hématologie, Institut Paoli-Calmettes, Marseille, France
| | - E D'Incan
- Département d'hématologie, Institut Paoli-Calmettes, Marseille, France
| | - C Rouzaud
- Département d'hématologie, Institut Paoli-Calmettes, Marseille, France
| | - V Gelsi-Boyer
- Département de Biologie des Tumeurs CRCM, Inserm, CNRS, Institut Paoli-Calmettes, Aix-Marseille Univ, Marseille, France
| | - A Murati
- Département de Biologie des Tumeurs, Institut Paoli-Calmettes, Marseille, France
| | - A C Lhoumeau
- Département de Biologie des Tumeurs, Institut Paoli-Calmettes, Marseille, France
| | - A Ittel
- Département de Biologie des Tumeurs, Institut Paoli-Calmettes, Marseille, France
| | - M J Mozziconacci
- Département de Biologie des Tumeurs, Institut Paoli-Calmettes, Marseille, France
| | - A S Alary
- Département de Biologie des Tumeurs, Institut Paoli-Calmettes, Marseille, France
| | - M-A Hospital
- Département d'hématologie, Institut Paoli-Calmettes, Marseille, France
| | - N Vey
- Département d'hématologie, CRCM, Inserm, CNRS, Institut Paoli-Calmettes, Aix-Marseille Univ, Marseille, France
| | - S Garciaz
- Département d'hématologie, CRCM, Inserm, CNRS, Institut Paoli-Calmettes, Aix-Marseille Univ, Marseille, France
| |
Collapse
|
5
|
Dawar S, Benitez MC, Lim Y, Dite TA, Yousef JM, Thio N, Garciaz S, Jackson TD, Milne JV, Dagley LF, Phillips WA, Kumar S, Clemons NJ. Caspase-2 protects against ferroptotic cell death. Cell Death Dis 2024; 15:182. [PMID: 38429264 PMCID: PMC10907636 DOI: 10.1038/s41419-024-06560-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2024] [Revised: 02/05/2024] [Accepted: 02/13/2024] [Indexed: 03/03/2024]
Abstract
Caspase-2, one of the most evolutionarily conserved members of the caspase family, is an important regulator of the cellular response to oxidative stress. Given that ferroptosis is suppressed by antioxidant defense pathways, such as that involving selenoenzyme glutathione peroxidase 4 (GPX4), we hypothesized that caspase-2 may play a role in regulating ferroptosis. This study provides the first demonstration of an important and unprecedented function of caspase-2 in protecting cancer cells from undergoing ferroptotic cell death. Specifically, we show that depletion of caspase-2 leads to the downregulation of stress response genes including SESN2, HMOX1, SLC7A11, and sensitizes mutant-p53 cancer cells to cell death induced by various ferroptosis-inducing compounds. Importantly, the canonical catalytic activity of caspase-2 is not required for its role and suggests that caspase-2 regulates ferroptosis via non-proteolytic interaction with other proteins. Using an unbiased BioID proteomics screen, we identified novel caspase-2 interacting proteins (including heat shock proteins and co-chaperones) that regulate cellular responses to stress. Finally, we demonstrate that caspase-2 limits chaperone-mediated autophagic degradation of GPX4 to promote the survival of mutant-p53 cancer cells. In conclusion, we document a novel role for caspase-2 as a negative regulator of ferroptosis in cells with mutant p53. Our results provide evidence for a novel function of caspase-2 in cell death regulation and open potential new avenues to exploit ferroptosis in cancer therapy.
Collapse
Affiliation(s)
- Swati Dawar
- Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia.
- Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, 3010, Australia.
| | - Mariana C Benitez
- Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia
- Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, 3010, Australia
| | - Yoon Lim
- Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, 5001, Australia
| | - Toby A Dite
- The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia
- Department of Medical Biology, University of Melbourne, Parkville, VIC, 3052, Australia
| | - Jumana M Yousef
- The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia
- Department of Medical Biology, University of Melbourne, Parkville, VIC, 3052, Australia
| | - Niko Thio
- Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia
| | - Sylvain Garciaz
- Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia
| | - Thomas D Jackson
- Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia
- Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, 3010, Australia
| | - Julia V Milne
- Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia
- Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, 3010, Australia
| | - Laura F Dagley
- The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia
- Department of Medical Biology, University of Melbourne, Parkville, VIC, 3052, Australia
| | - Wayne A Phillips
- Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia
- Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, 3010, Australia
- Department of Surgery (St Vincent's Hospital), The University of Melbourne, Parkville, VIC, 3010, Australia
| | - Sharad Kumar
- Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, 5001, Australia
- Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA, 5000, Australia
| | - Nicholas J Clemons
- Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia.
- Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, 3010, Australia.
| |
Collapse
|
6
|
Harbi S, Brac de la Perriere L, Bouchacourt B, Garciaz S, Pagliardini T, Calmels B, Cecile M, Lefloch AC, Hicheri Y, Hospital MA, Fürst S, Lemarie C, Braticevic C, Legrand F, Bekrieva E, Weiller PJ, Chabannon C, Vey N, Blaise D, Devillier R. Peripheral blood haploidentical hematopoietic cell transplantation for patients aged 70 years and over with acute myeloid leukemia or high-risk myelodysplastic syndrome. Bone Marrow Transplant 2024; 59:101-106. [PMID: 37923831 DOI: 10.1038/s41409-023-02134-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2023] [Revised: 10/04/2023] [Accepted: 10/17/2023] [Indexed: 11/06/2023]
Abstract
Haploidentical stem cell transplantation (Haplo-SCT) using non-myeloablative conditioning regimen (NMAC) has extended the feasibility of allogeneic transplantation, notably in older patients. However, there is few data specifically focusing on patients aged 70 years and over with AML and MDS. Thus the benefit of transplantation in this population is still debated. Here we report our single center experience of peripheral blood Haplo-SCT with NMAC and post-transplantation cyclophosphamide in AML and MDS patients aged 70 years and over. We analyzed 50 patients (27 AML, 23 MDS) with a median age of 72 years (70-77), 12/50 (24%) with active disease at Haplo-SCT. Cumulative incidence of grade 3-4 acute and moderate or severe chronic GVHD were 6% and 25%, respectively. Non-relapse mortality (NRM) at day +100 was 0%. NRM, relapse, PFS and OS at 3 years were 16%, 18%, 66%, and 69%, respectively. Among patients who were disease free at 2 years post Haplo-SCT, 88% are living without immunosuppressive treatment. Peripheral blood Haplo-SCT is feasible in selected AML/MDS patients over 70 years, without any early NRM. It produces long-term disease control and survival. Thus, age by itself should not be considered as a formal barrier to Haplo-SCT.
Collapse
Affiliation(s)
- Samia Harbi
- Hematology Department, Institut Paoli-Calmettes, Marseille, France
| | | | | | - Sylvain Garciaz
- Hematology Department, Institut Paoli-Calmettes, Aix Marseille Univ, CNRS, INSERM, CRCM, Marseille, France
| | | | - Boris Calmels
- Cell Therapy Facility, Institut Paoli-Calmettes, CIC-biotherapy, Marseille, France
| | - Maud Cecile
- Hematology Department, Institut Paoli-Calmettes, Marseille, France
| | - Anne-Charlotte Lefloch
- Hematology Department, Institut Paoli-Calmettes, Aix Marseille Univ, CNRS, INSERM, CRCM, Marseille, France
| | - Yosr Hicheri
- Hematology Department, Institut Paoli-Calmettes, Marseille, France
| | | | - Sabine Fürst
- Hematology Department, Institut Paoli-Calmettes, Marseille, France
| | - Claude Lemarie
- Cell Therapy Facility, Institut Paoli-Calmettes, CIC-biotherapy, Marseille, France
| | | | - Faezeh Legrand
- Hematology Department, Institut Paoli-Calmettes, Marseille, France
| | - Elena Bekrieva
- Hematology Department, Institut Paoli-Calmettes, Marseille, France
| | | | - Christian Chabannon
- Cell Therapy Facility, Institut Paoli-Calmettes, CIC-biotherapy, Marseille, France
| | - Norbert Vey
- Hematology Department, Institut Paoli-Calmettes, Aix Marseille Univ, CNRS, INSERM, CRCM, Marseille, France
| | - Didier Blaise
- Hematology Department, Institut Paoli-Calmettes, Aix Marseille Univ, CNRS, INSERM, CRCM, Marseille, France
| | - Raynier Devillier
- Hematology Department, Institut Paoli-Calmettes, Aix Marseille Univ, CNRS, INSERM, CRCM, Marseille, France.
| |
Collapse
|
7
|
Leblanc R, Ghossoub R, Goubard A, Castellano R, Fares J, Camoin L, Audebert S, Balzano M, Bou‐Tayeh B, Fauriat C, Vey N, Garciaz S, Borg J, Collette Y, Aurrand‐Lions M, David G, Zimmermann P. Downregulation of stromal syntenin sustains AML development. EMBO Mol Med 2023; 15:e17570. [PMID: 37819151 PMCID: PMC10630886 DOI: 10.15252/emmm.202317570] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2023] [Revised: 09/13/2023] [Accepted: 09/14/2023] [Indexed: 10/13/2023] Open
Abstract
The crosstalk between cancer and stromal cells plays a critical role in tumor progression. Syntenin is a small scaffold protein involved in the regulation of intercellular communication that is emerging as a target for cancer therapy. Here, we show that certain aggressive forms of acute myeloid leukemia (AML) reduce the expression of syntenin in bone marrow stromal cells (BMSC). Stromal syntenin deficiency, in turn, generates a pro-tumoral microenvironment. From serial transplantations in mice and co-culture experiments, we conclude that syntenin-deficient BMSC stimulate AML aggressiveness by promoting AML cell survival and protein synthesis. This pro-tumoral activity is supported by increased expression of endoglin, a classical marker of BMSC, which in trans stimulates AML translational activity. In short, our study reveals a vicious signaling loop potentially at the heart of AML-stroma crosstalk and unsuspected tumor-suppressive effects of syntenin that need to be considered during systemic targeting of syntenin in cancer therapy.
Collapse
Affiliation(s)
- Raphael Leblanc
- Team Spatio‐Temporal Regulation of Cell Signaling‐Scaffolds and Phosphoinositides, Equipe Labellisée Ligue 2018, Centre de Recherche en Cancérologie de Marseille (CRCM)Institut Paoli‐Calmettes, Aix‐Marseille Université, Inserm, CNRSMarseilleFrance
| | - Rania Ghossoub
- Team Spatio‐Temporal Regulation of Cell Signaling‐Scaffolds and Phosphoinositides, Equipe Labellisée Ligue 2018, Centre de Recherche en Cancérologie de Marseille (CRCM)Institut Paoli‐Calmettes, Aix‐Marseille Université, Inserm, CNRSMarseilleFrance
| | - Armelle Goubard
- TrGET Preclinical Platform, Centre de Recherche en Cancérologie de Marseille, Inserm, CNRSAix‐Marseille Université, Institut Paoli‐CalmettesMarseilleFrance
| | - Rémy Castellano
- TrGET Preclinical Platform, Centre de Recherche en Cancérologie de Marseille, Inserm, CNRSAix‐Marseille Université, Institut Paoli‐CalmettesMarseilleFrance
| | - Joanna Fares
- Team Spatio‐Temporal Regulation of Cell Signaling‐Scaffolds and Phosphoinositides, Equipe Labellisée Ligue 2018, Centre de Recherche en Cancérologie de Marseille (CRCM)Institut Paoli‐Calmettes, Aix‐Marseille Université, Inserm, CNRSMarseilleFrance
| | - Luc Camoin
- Proteomics and Mass Spectrometry Platform, Centre de Recherche en Cancérologie de MarseilleAix‐Marseille Université, Inserm, CNRS, Institut Paoli CalmettesMarseilleFrance
| | - Stephane Audebert
- Proteomics and Mass Spectrometry Platform, Centre de Recherche en Cancérologie de MarseilleAix‐Marseille Université, Inserm, CNRS, Institut Paoli CalmettesMarseilleFrance
| | - Marielle Balzano
- Team Spatio‐Temporal Regulation of Cell Signaling‐Scaffolds and Phosphoinositides, Equipe Labellisée Ligue 2018, Centre de Recherche en Cancérologie de Marseille (CRCM)Institut Paoli‐Calmettes, Aix‐Marseille Université, Inserm, CNRSMarseilleFrance
| | - Berna Bou‐Tayeh
- Team Immunity and Cancer, Centre de Recherche en Cancérologie de MarseilleAix‐Marseille Université, Inserm, CNRS, Institut Paoli CalmettesMarseilleFrance
| | - Cyril Fauriat
- Team Immunity and Cancer, Centre de Recherche en Cancérologie de MarseilleAix‐Marseille Université, Inserm, CNRS, Institut Paoli CalmettesMarseilleFrance
| | - Norbert Vey
- Aix‐Marseille Univ, Inserm, CNRS, Institut Paoli‐Calmettes, CRCMMarseilleFrance
| | - Sylvain Garciaz
- Aix‐Marseille Univ, Inserm, CNRS, Institut Paoli‐Calmettes, CRCMMarseilleFrance
| | - Jean‐Paul Borg
- Proteomics and Mass Spectrometry Platform, Centre de Recherche en Cancérologie de MarseilleAix‐Marseille Université, Inserm, CNRS, Institut Paoli CalmettesMarseilleFrance
| | - Yves Collette
- TrGET Preclinical Platform, Centre de Recherche en Cancérologie de Marseille, Inserm, CNRSAix‐Marseille Université, Institut Paoli‐CalmettesMarseilleFrance
| | - Michel Aurrand‐Lions
- Team Leuko/Stromal Interactions in Normal and Pathological Hematopoiesis, Centre de Recherche en Cancérologie de Marseille, Aix‐Marseille Université, Inserm, CNRS, Institut Paoli CalmettesMarseilleFrance
| | - Guido David
- Team Spatio‐Temporal Regulation of Cell Signaling‐Scaffolds and Phosphoinositides, Equipe Labellisée Ligue 2018, Centre de Recherche en Cancérologie de Marseille (CRCM)Institut Paoli‐Calmettes, Aix‐Marseille Université, Inserm, CNRSMarseilleFrance
- Department of Human GeneticsK U LeuvenLeuvenBelgium
| | - Pascale Zimmermann
- Team Spatio‐Temporal Regulation of Cell Signaling‐Scaffolds and Phosphoinositides, Equipe Labellisée Ligue 2018, Centre de Recherche en Cancérologie de Marseille (CRCM)Institut Paoli‐Calmettes, Aix‐Marseille Université, Inserm, CNRSMarseilleFrance
- Department of Human GeneticsK U LeuvenLeuvenBelgium
| |
Collapse
|
8
|
Cervera N, Guille A, Adélaïde J, Hospital M, Garciaz S, Mozziconacci M, Vey N, Gelsi‐Boyer V, Birnbaum D. Erythroleukemia: Classification. EJHaem 2023; 4:450-453. [PMID: 37206278 PMCID: PMC10188454 DOI: 10.1002/jha2.676] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 02/03/2023] [Revised: 02/28/2023] [Accepted: 03/02/2023] [Indexed: 05/21/2023]
Abstract
Acute erythroid leukemia (AEL) is a rare (2%-5%) form of acute myeloid leukemia (AML). Molecular alterations found in AEL resemble those of other AMLs. We report a classification of AELs in three major classes, with different prognosis and some specific features such as a tendency to mutual exclusion of mutations in epigenetic regulators and signaling genes.
Collapse
Affiliation(s)
- Nathalie Cervera
- Laboratoire d'Oncologie PrédictiveCentre de Recherche en Cancérologie de Marseille (CRCM)Institut Paoli‐CalmettesINSERM UMR 1068CNRS UMR725Aix‐Marseille UniversitéMarseilleFrance
| | - Arnaud Guille
- Laboratoire d'Oncologie PrédictiveCentre de Recherche en Cancérologie de Marseille (CRCM)Institut Paoli‐CalmettesINSERM UMR 1068CNRS UMR725Aix‐Marseille UniversitéMarseilleFrance
| | - José Adélaïde
- Laboratoire d'Oncologie PrédictiveCentre de Recherche en Cancérologie de Marseille (CRCM)Institut Paoli‐CalmettesINSERM UMR 1068CNRS UMR725Aix‐Marseille UniversitéMarseilleFrance
| | | | - Sylvain Garciaz
- Département d'HématologieInstitut Paoli‐CalmettesMarseilleFrance
| | | | - Norbert Vey
- Département d'HématologieInstitut Paoli‐CalmettesMarseilleFrance
| | - Véronique Gelsi‐Boyer
- Laboratoire d'Oncologie PrédictiveCentre de Recherche en Cancérologie de Marseille (CRCM)Institut Paoli‐CalmettesINSERM UMR 1068CNRS UMR725Aix‐Marseille UniversitéMarseilleFrance
- Département de BioPathologieInstitut Paoli‐CalmettesMarseilleFrance
| | - Daniel Birnbaum
- Laboratoire d'Oncologie PrédictiveCentre de Recherche en Cancérologie de Marseille (CRCM)Institut Paoli‐CalmettesINSERM UMR 1068CNRS UMR725Aix‐Marseille UniversitéMarseilleFrance
| |
Collapse
|
9
|
Garciaz S, Miller T, Collette Y, Vey N. Targeting regulated cell death pathways in acute myeloid leukemia. Cancer Drug Resist 2023; 6:151-168. [PMID: 37065864 PMCID: PMC10099605 DOI: 10.20517/cdr.2022.108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/10/2022] [Revised: 01/24/2023] [Accepted: 03/01/2023] [Indexed: 03/17/2023]
Abstract
The use of the BCL2 inhibitor venetoclax has transformed the management of patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy. By triggering intrinsic apoptosis, the drug is an excellent illustration of how our greater understanding of molecular cell death pathways can be translated into the clinic. Nevertheless, most venetoclax-treated patients will relapse, suggesting the need to target additional regulated cell death pathways. To highlight advances in this strategy, we review the recognized regulated cell death pathways, including apoptosis, necroptosis, ferroptosis and autophagy. Next, we detail the therapeutic opportunities to trigger regulated cell death in AML. Finally, we describe the main drug discovery challenges for regulated cell death inducers and their translation into clinical trials. A better knowledge of the molecular pathways regulating cell death represents a promising strategy to develop new drugs to cure resistant or refractory AML patients, particularly those resistant to intrinsic apoptosis.
Collapse
Affiliation(s)
- Sylvain Garciaz
- Hematology Department, Integrative Structural and Chemical Biology, Aix-Marseille Université, Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille 13009, France
| | - Thomas Miller
- Integrative Structural and Chemical Biology, Aix-Marseille Université, Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille 13009, France
| | - Yves Collette
- Integrative Structural and Chemical Biology, Aix-Marseille Université, Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille 13009, France
| | - Norbert Vey
- Hematology Department, Aix-Marseille Université, Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille 13009, France
| |
Collapse
|
10
|
Garciaz S, Vey N. [Myelodysplastic syndromes]. Rev Prat 2023; 73:221-226. [PMID: 36916268] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 03/16/2023]
Affiliation(s)
- Sylvain Garciaz
- Université Aix-Marseille, Institut Paoli-Calmettes et Centre de recherche en cancérologie de Marseille, Marseille, France
| | - Norbert Vey
- Université Aix-Marseille, Institut Paoli-Calmettes et Centre de recherche en cancérologie de Marseille, Marseille, France
| |
Collapse
|
11
|
Garciaz S, Hospital MA. FMS-Like Tyrosine Kinase 3 Inhibitors in the Treatment of Acute Myeloid Leukemia: An Update on the Emerging Evidence and Safety Profile. Onco Targets Ther 2023; 16:31-45. [PMID: 36698434 PMCID: PMC9869913 DOI: 10.2147/ott.s236740] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2022] [Accepted: 01/11/2023] [Indexed: 01/19/2023] Open
Abstract
FMS-like tyrosine kinase 3 (FLT3) is one of the most frequently mutated genes in acute myeloid leukemia (AML). Approximately 30% of the adult cases harbor an internal tandem duplication (FLT3-ITD) and 5-10% a tyrosine kinase domain (TKD) amino acid substitution (FLT3-TKD). The treatment paradigm of AML patients harboring FLT3 mutations (30%) has been modified by the discovery of tyrosine kinase inhibitors. First- and second-generation inhibitors classify FLT3 inhibitors according to FLT3 specificity: first-generation FLT3 inhibitors include sorafenib and midostaurin and second-generation inhibitors are represented by quizartinib, gilteritinib and crenolanib, among others. Activity of these inhibitors depends on their mechanism of receptor binding (active vs inactive conformation) and efficacy against the FLT3-ITD and -TKD mutations (type 1 inhibitors are active both on FLT3-ITD and TKD, whereas type 2 inhibitors are active only on FLT3-ITD). The FLT3 inhibitors sorafenib, midostaurin, quizartinib and gilteritinib have been tested in monotherapy in several settings including refractory or relapsed AML (R/R AML), post-transplant maintenance as well as in combination with intensive chemotherapy (ICT) or non-intensity regimens. The results of published randomized studies support the use of sorafenib in a post-transplant setting (SORMAIN trial), midostaurin in combination with ICT based (RATIFY trial) and gilteritinib for R/R AML (ADMIRAL trial). Gilteritinib in combination with hypomethylating agent as well as quizartinib are not supported by solid randomized trial results for their use in FLT3-mutated AML patients.
Collapse
Affiliation(s)
- Sylvain Garciaz
- Department of Hematology, Institut Paoli-Calmettes, Aix-Marseille Université, Centre National de la Recherche Scientifique, UMR7258, Centre de Recherche en Cancérologie de Marseille, INSERM U1068, Marseille, France,Correspondence: Sylvain Garciaz, Institut Paoli-Calmettes, Hematology Department, 232 Bd Sainte-Marguerite, Marseille, 13009, France, Tel + 33 4 91 22 37 54, Fax + 33 4 91 22 30 63, Email
| | - Marie-Anne Hospital
- Department of Hematology, Institut Paoli-Calmettes, Aix-Marseille Université, Centre National de la Recherche Scientifique, UMR7258, Centre de Recherche en Cancérologie de Marseille, INSERM U1068, Marseille, France
| |
Collapse
|
12
|
Marmouset V, Decroocq J, Garciaz S, Etienne G, Belhabri A, Bertoli S, Gastaud L, Simand C, Chantepie S, Uzunov M, Genthon A, Berthon C, Chiche E, Dumas PY, Vargaftig J, Salmeron G, Lemasle E, Tavernier E, Delage J, Loirat M, Morineau N, Blanc-Durand F, Pautier P, Vergé V, Auger N, Thomas M, Stefani L, Lepelley M, Boyer T, Thepot S, Gourin MP, Bourquard P, Duchmann M, Morice PM, Michallet M, Adès L, Fenaux P, Récher C, Dombret H, Pagès A, Marzac C, Leary A, Micol JB. Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience. Clin Cancer Res 2022; 28:5211-5220. [PMID: 36201165 DOI: 10.1158/1078-0432.ccr-22-1622] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2022] [Revised: 07/27/2022] [Accepted: 10/04/2022] [Indexed: 01/24/2023]
Abstract
PURPOSE To provide insights into the diagnosis and management of therapy-related myeloid neoplasms (t-MN) following PARP inhibitors (PARPi). EXPERIMENTAL DESIGN In a French cancer center, we identified and described the profiles of 13 t-MN diagnosed among 37 patients with ovarian cancer referred to hematology consultation for cytopenia under PARPi. Next, we described these 13 t-MN post-PARPi among 37 t-MN post ovarian cancer according to PARPi exposure. Finally, we described 69 t-MN post-PARPi in a national cohort. RESULTS From 2016 to 2021, cumulative incidence of t-MN was 3.5% (13/373) among patients with ovarian cancer treated with PARPi. At time of hematologic consultation, patients with t-MN had a longer PARPi exposure (9 vs. 3 months, P = 0.01), lower platelet count (74 vs. 173 G/L, P = 0.0005), and more cytopenias (2 vs. 1, P = 0.0005). Compared with t-MN not exposed to PARPi, patients with t-MN-PARPi had more BRCA1/2 germline mutation (61.5% vs. 0%, P = 0.03) but similar overall survival (OS). In the national cohort, most t-MN post-PARPi had a complex karyotype (61%) associated with a high rate of TP53 mutation (71%). Median OS was 9.6 months (interquartile range, 4-14.6). In multivariate analysis, a longer time between end of PARPi and t-MN (HR, 1.046; P = 0.02), olaparib compared with other PARPi (HR, 5.82; P = 0.003) and acute myeloid leukemia (HR, 2.485; P = 0.01) were associated with shorter OS. CONCLUSIONS In a large series, we described a high incidence of t-MN post-PARPi associated with unfavorable cytogenetic and molecular abnormalities leading to poor OS. Early detection is crucial, particularly in cases of delayed cytopenia.
Collapse
Affiliation(s)
- Vincent Marmouset
- Department of Hematology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
- Interception Program, Personalized Cancer Prevention Center, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Justine Decroocq
- Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Service d'Hématologie Clinique, Hôpital Cochin, Paris, France
| | - Sylvain Garciaz
- Institut Paoli Calmettes, Marseille, France
- Cancer Research Center of Marseille, INSERM U1068, Aix-Marseille University, Marseille, France
| | | | - Amine Belhabri
- Department of Oncology, Centre Leon Berard, Lyon, France
| | - Sarah Bertoli
- Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Université Toulouse III Paul Sabatier, Toulouse, France
| | | | - Célestine Simand
- Department of Hematology, Institute for Cancer Strasbourg-Europe (ICANS), Strasbourg University, Strasbourg, France
| | - Sylvain Chantepie
- Department of Clinical Hematology, Caen University Hospital, Caen, France
| | - Madalina Uzunov
- Service d'hématologie adulte, Hôpital Pitié-Salpêtrière, Paris, France
| | - Alexis Genthon
- Department of Clinical Hematology, Saint Antoine Hospital, Sorbonne University, INSERM UMR-S 938, Paris, France
| | - Céline Berthon
- Department of Hematology, CHU Lille, Lille, France
- University of Lille, CNRS, Inserm, CHU Lille, IRCL, UMR9020 - UMR1277 - Canther - Cancer heterogeneity, plasticity and resistance to therapies, Lille, France
| | | | - Pierre-Yves Dumas
- CHU Bordeaux, Service d'Hématologie Clinique et de Thérapie Cellulaire, Bordeaux, France
| | | | | | - Emilie Lemasle
- Département d'hématologie, Hôpital Henri Becquerel, Rouen, France
| | - Emmanuelle Tavernier
- Hématologie, Institut de Cancérologie-Hématologie Universitaire de Saint Etienne, France
| | - Jérémy Delage
- Département d'hématologie clinique, Saint Eloi, Montpellier, France
| | - Marion Loirat
- Service d'hématologie, Hôpital Saint Nazaire, Saint-Nazaire, France
| | | | - Félix Blanc-Durand
- Department of Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
- INSERM U981, Villejuif, France
- Interception Program, Personalized Cancer Prevention Center, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Patricia Pautier
- Department of Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
- INSERM U981, Villejuif, France
- Interception Program, Personalized Cancer Prevention Center, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Véronique Vergé
- Department of Biology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Nathalie Auger
- Department of Biology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | | | | | - Marion Lepelley
- Centre Régional de Pharmacovigilance - Addictovigilance, CHU de Grenoble-Alpes, France
| | - Thomas Boyer
- Laboratoire d'Hématologie, Centre Hospitalier Universitaire d'Amiens, Amiens, France
| | | | | | | | - Matthieu Duchmann
- Université de Paris, Génomes, Biologie Cellulaire et Thérapeutique Unité (U)944, INSERM, Centre National de la Recherche Scientifique (CNRS), Paris, France
| | - Pierre-Marie Morice
- Department of Clinical Hematology, Caen University Hospital, Caen, France
- UNICAEN, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancer Prevention and Treatment), Normandie University, Caen, France
| | | | - Lionel Adès
- Hématologie Sénior Hôpital Saint Louis, Assistance publique hôpitaux de paris, and Université de Paris Cité, Paris, France
| | - Pierre Fenaux
- Hématologie Sénior Hôpital Saint Louis, Assistance publique hôpitaux de paris, and Université de Paris Cité, Paris, France
| | - Christian Récher
- Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Université Toulouse III Paul Sabatier, Toulouse, France
| | - Hervé Dombret
- Adult Hematology Department, Saint-Louis Hospital, APHP, URP3518, Institut de Recherche Saint-Louis, Université de Paris, Paris, France
| | - Arnaud Pagès
- Bureau de Biostatistique et d'Épidémiologie - Gustave Roussy Équipe Oncostat - CESP U1018 - Inserm, France
| | - Christophe Marzac
- Department of Biology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Alexandra Leary
- Department of Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
- INSERM U981, Villejuif, France
- Interception Program, Personalized Cancer Prevention Center, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Jean-Baptiste Micol
- Department of Hematology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
- Interception Program, Personalized Cancer Prevention Center, Gustave Roussy, Université Paris-Saclay, Villejuif, France
- INSERM U1287, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| |
Collapse
|
13
|
Chan KL, Gomez J, Cardinez C, Kumari N, Sparbier CE, Lam EYN, Yeung MM, Garciaz S, Kuzich JA, Ong DM, Brown FC, Chan YC, Vassiliadis D, Wainwright EN, Motazedian A, Gillespie A, Fennell KA, Lai J, House IG, Macpherson L, Ang CS, Dawson SJ, Beavis PA, Wei AH, Burr ML, Dawson MA. Inhibition of the CtBP complex and FBXO11 enhances MHC class II expression and anti-cancer immune responses. Cancer Cell 2022; 40:1190-1206.e9. [PMID: 36179686 PMCID: PMC7615013 DOI: 10.1016/j.ccell.2022.09.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/13/2021] [Revised: 07/22/2022] [Accepted: 09/04/2022] [Indexed: 11/24/2022]
Abstract
There is increasing recognition of the prognostic significance of tumor cell major histocompatibility complex (MHC) class II expression in anti-cancer immunity. Relapse of acute myeloid leukemia (AML) following allogeneic stem cell transplantation (alloSCT) has recently been linked to MHC class II silencing in leukemic blasts; however, the regulation of MHC class II expression remains incompletely understood. Utilizing unbiased CRISPR-Cas9 screens, we identify that the C-terminal binding protein (CtBP) complex transcriptionally represses MHC class II pathway genes, while the E3 ubiquitin ligase complex component FBXO11 mediates degradation of CIITA, the principal transcription factor regulating MHC class II expression. Targeting these repressive mechanisms selectively induces MHC class II upregulation across a range of AML cell lines. Functionally, MHC class II+ leukemic blasts stimulate antigen-dependent CD4+ T cell activation and potent anti-tumor immune responses, providing fundamental insights into the graft-versus-leukemia effect. These findings establish the rationale for therapeutic strategies aimed at restoring tumor-specific MHC class II expression to salvage AML relapse post-alloSCT and also potentially to enhance immunotherapy outcomes in non-myeloid malignancies.
Collapse
Affiliation(s)
- Kah Lok Chan
- Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia; Department of Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC 3000, Australia
| | - Juliana Gomez
- Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Division of Genome Science and Cancer, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT 2601, Australia
| | - Chelisa Cardinez
- Division of Genome Science and Cancer, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT 2601, Australia
| | - Nishi Kumari
- Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia
| | - Christina E Sparbier
- Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia
| | - Enid Y N Lam
- Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia
| | - Miriam M Yeung
- Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia
| | - Sylvain Garciaz
- Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Aix-Marseille University, INSERM U1068, CNRS, Institut Paoli-Calmettes, 13009 Marseille, France
| | - James A Kuzich
- Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia
| | - Doen Ming Ong
- Australian Centre for Blood Diseases, Monash University, Melbourne, VIC 3004, Australia; Department of Haematology, The Alfred Hospital, Melbourne, VIC 3004, Australia
| | - Fiona C Brown
- Australian Centre for Blood Diseases, Monash University, Melbourne, VIC 3004, Australia
| | - Yih-Chih Chan
- Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia
| | - Dane Vassiliadis
- Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia
| | - Elanor N Wainwright
- Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia
| | - Ali Motazedian
- Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia
| | | | - Katie A Fennell
- Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia
| | - Junyun Lai
- Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia
| | - Imran G House
- Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia
| | - Laura Macpherson
- Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia
| | - Ching-Seng Ang
- Melbourne Mass Spectrometry and Proteomics Facility, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, VIC 3010, Australia
| | - Sarah-Jane Dawson
- Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia; Centre for Cancer Research, The University of Melbourne, Parkville, VIC 3000, Australia
| | - Paul A Beavis
- Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia
| | - Andrew H Wei
- Australian Centre for Blood Diseases, Monash University, Melbourne, VIC 3004, Australia; Department of Haematology, The Alfred Hospital, Melbourne, VIC 3004, Australia
| | - Marian L Burr
- Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia; Division of Genome Science and Cancer, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT 2601, Australia; Department of Anatomical Pathology, ACT Pathology, Canberra Health Services, Canberra, ACT 2606, Australia.
| | - Mark A Dawson
- Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia; Department of Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC 3000, Australia; Centre for Cancer Research, The University of Melbourne, Parkville, VIC 3000, Australia.
| |
Collapse
|
14
|
Marmouset V, Decroocq J, Garciaz S, Etienne G, Belhabri A, Gastaud L, Bertoli S, Simand C, Uzunov M, Chantepie S, Genthon A, Berthon C, Chiche E, Dumas PY, Blanc-Durand F, Pautier P, Pages A, Marzac C, Leary A, Micol JB. Therapy related myeloid neoplasms (t-MNs) following PARP inhibitors (PARPi): Real-life experience. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.16_suppl.7057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7057 Background: PARPi have shown promising results in several cancers, especially breast (BC) and ovarian cancer (OC), but may be associated with an increased risk of t-MNs. A careful monitoring of hematologic toxicity to exclude this risk is necessary. Here we described, in a real-life setting, the management of these adverse effect. Methods: First,we described, in a large cancer center, the profile of t-MN patients among OC patients treated with PARPi addressed in hematological consultation for cytopenias. Secondly, we compared t-MN post OC characteristics according to previous exposition to PARPi. Lastly, we described a large national observatory of 69 t-MNs post PARPi to decipher specific characteristics of these t-MNs. Results: From 2016 to 2021, among 373 PARPi treated patients for OC, 37 (10%) were explored for cytopenia’s leading to 13 (3,5%) t-MNs diagnosis. No differences were seen in terms of age, BRCA1/2 status, type of PARPi, hemoglobin level but patients with t-MNs developed delayed cytopenias post-PARPi initiation (11 months vs to 4 months, p = 0.01), had a longer PARPi exposition (9 months vs 3 months, p = 0.01), lower platelets level (74 G/L vs 173 G/L, p = 0.0005), more cytopenias (2 vs 1, p = 0.0005). 77% of t-MNs patients had a TP53 mutated t-MNs, 33% of patients w/o t-MNs had TP53 mutated clonal hematopoiesis. In the last 20 years, 37 patients were addressed for t-MN post OC at our institute, with an increased incidence of 50% during the last 6 years. Compared to t-MN not exposed to PARPi, t-MN-PARPi patients had more BRCA1/2 predisposition (61.5% vs 0% p = 0.03), their OC tended to be non-progressive (CR/PR/SD = 62.5% vs 38.5%, p = 0.3) and tend to have more TP53 mutated t-MNs (77% vs 47%, p = 0.1). Median OS for t-MNs post PARPi was poor at 8.2 months (CI95% [2.03-18.7]) but not significantly different form other t-MNs (p = 0.8). We then studied 69 t-MNs-PARPi including 28 AML and 41 MDS in patient with history of OC (75%), BC (9%) or both (16%). Median age was 64 years, 80% received Olaparib, 72.5% had a BRCA1/2 predisposition. Median time between cancer diagnosis and initiation of PARPi was 44 months and median duration of PARPi treatment was 14 months. History of haematological toxicity secondary to PARPi was reported in 51% of patients. Karyotype was often complex (61%) associated with a high rate of TP53 mutation (70.5%). Median OS was 9.7 months (CI95%, 5.3-13.9). In multivariate analysis, a longer delay between the end of PARPi treatment and t-NM diagnosis (HR 1.046, p = 0.02), as well Olaparib treatment compared to others PARPi (HR 5.82, p = 0.003 and AML diagnosis (HR 2.485, p = 0.01) were associated with shorter OS. Conclusions: We describe in a large series a higher incidence of t-MNs post PARPi than previously reported. Unfavorable cytogenetic and molecular abnormalities associated with these t-MNS explained the poor OS. Early detection is crucial particularly in case of delayed appearance of cytopenias.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Sarah Bertoli
- Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France
| | | | | | - Sylvain Chantepie
- Institut d’Hématologie de Basse-Normandie, Centre Hospitalier Universitaire de Caen, Caen, France
| | | | | | | | | | | | - Patricia Pautier
- GINECO, French Sarcoma Group and Gustave Roussy Cancer Center, Villejuif, France
| | | | | | - Alexandra Leary
- Gustave-Roussy Cancer Campus, Villejuif, and Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens, Villejuif, France
| | | | | |
Collapse
|
15
|
Garciaz S, Guirguis AA, Müller S, Brown FC, Chan YC, Motazedian A, Rowe CL, Kuzich JA, Chan KL, Tran K, Smith L, MacPherson L, Liddicoat B, Lam EY, Cañeque T, Burr ML, Litalien V, Pomilio G, Poplineau M, Duprez E, Dawson SJ, Ramm G, Cox AG, Brown KK, Huang DC, Wei AH, McArthur K, Rodriguez R, Dawson MA. Pharmacologic Reduction of Mitochondrial Iron Triggers a Noncanonical BAX/BAK-Dependent Cell Death. Cancer Discov 2022; 12:774-791. [PMID: 34862195 PMCID: PMC9390741 DOI: 10.1158/2159-8290.cd-21-0522] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2021] [Revised: 10/18/2021] [Accepted: 11/29/2021] [Indexed: 01/07/2023]
Abstract
Cancer cell metabolism is increasingly recognized as providing an exciting therapeutic opportunity. However, a drug that directly couples targeting of a metabolic dependency with the induction of cell death in cancer cells has largely remained elusive. Here we report that the drug-like small-molecule ironomycin reduces the mitochondrial iron load, resulting in the potent disruption of mitochondrial metabolism. Ironomycin promotes the recruitment and activation of BAX/BAK, but the resulting mitochondrial outer membrane permeabilization (MOMP) does not lead to potent activation of the apoptotic caspases, nor is the ensuing cell death prevented by inhibiting the previously established pathways of programmed cell death. Consistent with the fact that ironomycin and BH3 mimetics induce MOMP through independent nonredundant pathways, we find that ironomycin exhibits marked in vitro and in vivo synergy with venetoclax and overcomes venetoclax resistance in primary patient samples. SIGNIFICANCE Ironomycin couples targeting of cellular metabolism with cell death by reducing mitochondrial iron, resulting in the alteration of mitochondrial metabolism and the activation of BAX/BAK. Ironomycin induces MOMP through a different mechanism to BH3 mimetics, and consequently combination therapy has marked synergy in cancers such as acute myeloid leukemia. This article is highlighted in the In This Issue feature, p. 587.
Collapse
Affiliation(s)
- Sylvain Garciaz
- Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia
- Aix-Marseille University, INSERM U1068, CNRS, Institut Paoli-Calmettes, Marseille, France
| | - Andrew A. Guirguis
- Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia
| | - Sebastian Müller
- Institut Curie, PSL Research University, CNRS UMR3666, INSERM U1143, Chemical Biology of Cancer, Paris, France
| | - Fiona C. Brown
- Australian Centre for Blood Diseases, Monash University, Melbourne, Victoria, Australia
| | - Yih-Chih Chan
- Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia
| | - Ali Motazedian
- Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia
| | - Caitlin L. Rowe
- Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Melbourne, Victoria, Australia
| | - James A. Kuzich
- Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia
| | - Kah Lok Chan
- Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia
| | - Kevin Tran
- Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia
| | - Lorey Smith
- Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia
| | - Laura MacPherson
- Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia
| | - Brian Liddicoat
- Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia
| | - Enid Y.N. Lam
- Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia
| | - Tatiana Cañeque
- Institut Curie, PSL Research University, CNRS UMR3666, INSERM U1143, Chemical Biology of Cancer, Paris, France
| | - Marian L. Burr
- Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia
| | - Véronique Litalien
- Australian Centre for Blood Diseases, Monash University, Melbourne, Victoria, Australia
| | - Giovanna Pomilio
- Australian Centre for Blood Diseases, Monash University, Melbourne, Victoria, Australia
| | - Mathilde Poplineau
- Aix-Marseille University, INSERM U1068, CNRS, Institut Paoli-Calmettes, Marseille, France
| | - Estelle Duprez
- Aix-Marseille University, INSERM U1068, CNRS, Institut Paoli-Calmettes, Marseille, France
| | - Sarah-Jane Dawson
- Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia
- Centre for Cancer Research, University of Melbourne, Melbourne, Victoria, Australia
| | - Georg Ramm
- Monash Ramaciotti Centre for Cryo Electron Microscopy, Monash University, Melbourne, Victoria, Australia
| | - Andrew G. Cox
- Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia
- Department of Biochemistry and Pharmacology, University of Melbourne, Melbourne, Victoria, Australia
| | - Kristin K. Brown
- Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia
- Department of Biochemistry and Pharmacology, University of Melbourne, Melbourne, Victoria, Australia
| | - David C.S. Huang
- The Walter and Eliza Hall Institute of Medical Research, Parkville, Melbourne, Victoria, Australia
| | - Andrew H. Wei
- Australian Centre for Blood Diseases, Monash University, Melbourne, Victoria, Australia
| | - Kate McArthur
- Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Melbourne, Victoria, Australia
| | - Raphaël Rodriguez
- Institut Curie, PSL Research University, CNRS UMR3666, INSERM U1143, Chemical Biology of Cancer, Paris, France
| | - Mark A. Dawson
- Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia
- Centre for Cancer Research, University of Melbourne, Melbourne, Victoria, Australia
| |
Collapse
|
16
|
Costes-Tertrais D, Hueso T, Gastinne T, Thieblemont C, Oberic L, Bouabdallah K, Garciaz S, Tchernonog E, Dartigeas C, Ribrag V, Fogarty P, Casasnovas RO, Houot R, Delette C, Malak S, Fornecker LM, Gressin R, Damaj G, Le Gouill S. Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study. Bone Marrow Transplant 2022; 57:627-632. [PMID: 35149851 DOI: 10.1038/s41409-022-01596-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2021] [Revised: 01/18/2022] [Accepted: 01/19/2022] [Indexed: 11/09/2022]
Abstract
Cytarabine-based immuno-chemotherapy followed by autologous stem cell transplantation (ASCT) consolidation is standard of care for fit patients with Mantle Cell Lymphoma (MCL). BEAM (Carmustine, Etoposide, Aracytine, Melphalan) is among the most frequently used conditioning regimen. Studies comparing BEAM with Bendamustine-EAM (BeEAM) have suggested that patients treated with BeEAM have a better progression-free survival (PFS). We performed a cross-study analysis to better evaluate BeEAM. Thirty-five patients from a retrospective study who received R-DHAP/BeEAM were compared to 245 patients from the LyMa trial (NCT00921414) who all received R-DHAP followed by R-BEAM. PFS and Overall Survival (OS) were estimated using Kaplan-Meier methods. At 2 years there was no difference between R-BEAM and BeEAM in either PFS (84.9% versus 87.9%; p = 0.95) or OS (91.8% versus 94.2%; p = 0.30). Analyses were repeated on a propensity score to reduce biases. Each patient from the BeEAM cohort (n = 30) was matched to three patients from the R-BEAM cohort (n = 90) for age, sex, MIPI score, pre-transplant status disease and rituximab maintenance (RM). PFS and OS at 2 years remained similar between R-BEAM and BeEAM with more renal toxicity in BeEAM group. MCL patients who received R-DHAP induction before ASCT have similar outcome after R-BEAM or BeEAM conditioning regimen.
Collapse
Affiliation(s)
- Domitille Costes-Tertrais
- Department of Hematology, CHU de Nantes, University Hospital of Nantes, Nantes, France.,School of Medicine, Nantes University, Nantes, France
| | - Thomas Hueso
- Department of Hematology, APHP-Avicenne Hospital, Paris, France.,Sorbonne University Paris Nord, Bobigny, France
| | - Thomas Gastinne
- Department of Hematology, CHU de Nantes, University Hospital of Nantes, Nantes, France
| | - Catherine Thieblemont
- Department of Hemato-oncology, APHP-Saint-Louis Hospital, Paris, France.,Diderot Sorbonne Paris-Cité University, Paris, France.,Descartes University, Paris, France
| | - Lucie Oberic
- Department of Clinical Hematology, Toulouse Oncopole, Toulouse, France
| | - Krimo Bouabdallah
- Department of Clinical Hematology, Bordeaux University Hospital, Bordeaux, France
| | - Sylvain Garciaz
- Department of Clinical Hematology, Paoli Calmettes Institute, Marseille, France
| | - Emmanuelle Tchernonog
- Department of Clinical Hematology, Montpellier University Hospital, Montpellier, France
| | - Caroline Dartigeas
- Department of Clinical Hematology, Tours University Hospital, Tours, France
| | | | | | - René-Olivier Casasnovas
- Department of Clinical Hematology, François Mitterrand University Hospital, Dijon, France.,Inserm UMR 1231, Dijon, France
| | - Roch Houot
- Department of Clinical Hematology, Rennes University Hospital, F-35033, Rennes, France.,MICMAC-Inserm UMR 1236, Rennes University, F-35000, Rennes, France
| | - Caroline Delette
- Department of Clinical Hematology, Amiens University Hospital, Amiens, France
| | - Sandra Malak
- Department of Clinical Hematology, Curie Institute, René Huguenin Hospital, Saint-Cloud, France
| | | | - Remy Gressin
- Department of Clinical Hematology, Grenoble University Hospital, Grenoble, France
| | - Gandhi Damaj
- Department of Clinical Hematology, Caen University Hospital, F-14000, Caen, France.,School of Medicine, Normandy University, F-14000, Caen, France
| | - Steven Le Gouill
- Department of Hematology, CHU de Nantes, University Hospital of Nantes, Nantes, France. .,Now at Curie Insitute, Paris, France.
| |
Collapse
|
17
|
Garciaz S, N'guyen Dasi L, Finetti P, Chevalier C, Vernerey J, Poplineau M, Platet N, Audebert S, Pophillat M, Camoin L, Bertucci F, Calmels B, Récher C, Birnbaum D, Chabannon C, Vey N, Duprez E. Epigenetic down-regulation of the HIST1 locus predicts better prognosis in acute myeloid leukemia with NPM1 mutation. Clin Epigenetics 2019; 11:141. [PMID: 31606046 PMCID: PMC6790061 DOI: 10.1186/s13148-019-0738-6] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2019] [Accepted: 09/05/2019] [Indexed: 12/22/2022] Open
Abstract
BACKGROUND The epigenetic machinery is frequently altered in acute myeloid leukemia. Focusing on cytogenetically normal (CN) AML, we previously described an abnormal H3K27me3 enrichment covering 70 kb on the HIST1 cluster (6.p22) in CN-AML patient blasts. Here, we further investigate the molecular, functional, and prognosis significance of this epigenetic alteration named H3K27me3 HIST1 in NPM1-mutated (NPM1mut) CN-AML. RESULTS We found that three quarter of the NPM1mut CN-AML patients were H3K27me3 HIST1high. H3K27me3 HIST1high group of patients was associated with a favorable outcome independently of known molecular risk factors. In gene expression profiling, the H3K27me3 HIST1high mark was associated with lower expression of the histone genes HIST1H1D, HIST1H2BG, HIST1H2AE, and HIST1H3F and an upregulation of genes involved in myelomonocytic differentiation. Mass spectrometry analyses confirmed that the linker histone protein H1d, but not the other histone H1 subtypes, was downregulated in the H3K27me3 HIST1high group of patients. H1d knockdown primed ATRA-mediated differentiation of OCI-AML3 and U937 AML cell lines, as assessed on CD11b/CD11c markers, morphological and gene expression analyses. CONCLUSIONS Our data suggest that NPM1mut AML prognosis depends on the epigenetic silencing of the HIST1 cluster and that, among the H3K27me3 silenced histone genes, HIST1H1D plays a role in AML blast differentiation.
Collapse
Affiliation(s)
- Sylvain Garciaz
- Epigenetic Factors in Normal and Malignant Hematopoiesis Team, Aix Marseille University, CNRS, Inserm, Institut Paoli-Calmettes, CRCM, 27 Boulevard Lei Roure, 13273, Marseille Cedex 09, France
| | - Lia N'guyen Dasi
- Epigenetic Factors in Normal and Malignant Hematopoiesis Team, Aix Marseille University, CNRS, Inserm, Institut Paoli-Calmettes, CRCM, 27 Boulevard Lei Roure, 13273, Marseille Cedex 09, France
| | - Pascal Finetti
- Predictive Oncology Laboratory, CRCM, Inserm, U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, Marseille, France
| | - Christine Chevalier
- Epigenetic Factors in Normal and Malignant Hematopoiesis Team, Aix Marseille University, CNRS, Inserm, Institut Paoli-Calmettes, CRCM, 27 Boulevard Lei Roure, 13273, Marseille Cedex 09, France.,Institut Pasteur, G5 Chromatin and Infection, Paris, France
| | - Julien Vernerey
- Epigenetic Factors in Normal and Malignant Hematopoiesis Team, Aix Marseille University, CNRS, Inserm, Institut Paoli-Calmettes, CRCM, 27 Boulevard Lei Roure, 13273, Marseille Cedex 09, France
| | - Mathilde Poplineau
- Epigenetic Factors in Normal and Malignant Hematopoiesis Team, Aix Marseille University, CNRS, Inserm, Institut Paoli-Calmettes, CRCM, 27 Boulevard Lei Roure, 13273, Marseille Cedex 09, France
| | - Nadine Platet
- Epigenetic Factors in Normal and Malignant Hematopoiesis Team, Aix Marseille University, CNRS, Inserm, Institut Paoli-Calmettes, CRCM, 27 Boulevard Lei Roure, 13273, Marseille Cedex 09, France
| | - Stéphane Audebert
- Aix-Marseille University, Inserm, CNRS, Institut Paoli-Calmettes, CRCM, Marseille Protéomique, Marseille, France
| | - Matthieu Pophillat
- Aix-Marseille University, Inserm, CNRS, Institut Paoli-Calmettes, CRCM, Marseille Protéomique, Marseille, France
| | - Luc Camoin
- Aix-Marseille University, Inserm, CNRS, Institut Paoli-Calmettes, CRCM, Marseille Protéomique, Marseille, France
| | - François Bertucci
- Predictive Oncology Laboratory, CRCM, Inserm, U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, Marseille, France
| | - Boris Calmels
- Epigenetic Factors in Normal and Malignant Hematopoiesis Team, Aix Marseille University, CNRS, Inserm, Institut Paoli-Calmettes, CRCM, 27 Boulevard Lei Roure, 13273, Marseille Cedex 09, France.,Aix-Marseille University, Inserm, CNRS, Institut Paoli-Calmettes, CRCM, Centre d'Investigations Cliniques en Biothérapies, Marseille, France
| | - Christian Récher
- Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France Université Toulouse III Paul Sabatier, Cancer Research Center of Toulouse, UMR1037-INSERM, ERL5294 CNRS, Toulouse, France
| | - Daniel Birnbaum
- Predictive Oncology Laboratory, CRCM, Inserm, U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, Marseille, France
| | - Christian Chabannon
- Epigenetic Factors in Normal and Malignant Hematopoiesis Team, Aix Marseille University, CNRS, Inserm, Institut Paoli-Calmettes, CRCM, 27 Boulevard Lei Roure, 13273, Marseille Cedex 09, France.,Aix-Marseille University, Inserm, CNRS, Institut Paoli-Calmettes, CRCM, Centre d'Investigations Cliniques en Biothérapies, Marseille, France
| | - Norbert Vey
- Aix-Marseille University, Inserm, CNRS, Institut Paoli-Calmettes, CRCM, Marseille, France
| | - Estelle Duprez
- Epigenetic Factors in Normal and Malignant Hematopoiesis Team, Aix Marseille University, CNRS, Inserm, Institut Paoli-Calmettes, CRCM, 27 Boulevard Lei Roure, 13273, Marseille Cedex 09, France.
| |
Collapse
|
18
|
Koubi M, Poplineau M, Vernerey J, N'Guyen L, Tiberi G, Garciaz S, El-Kaoutari A, Maqbool MA, Andrau JC, Guillouf C, Saurin AJ, Duprez E. Regulation of the positive transcriptional effect of PLZF through a non-canonical EZH2 activity. Nucleic Acids Res 2019; 46:3339-3350. [PMID: 29425303 PMCID: PMC5909434 DOI: 10.1093/nar/gky080] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2018] [Accepted: 01/31/2018] [Indexed: 11/13/2022] Open
Abstract
The transcription factor PLZF (promyelocytic leukemia zinc finger protein) acts as an epigenetic regulator balancing self-renewal and differentiation of hematopoietic cells through binding to various chromatin-modifying factors. First described as a transcriptional repressor, PLZF is also associated with active transcription, although the molecular bases underlying the differences are unknown. Here, we reveal that in a hematopoietic cell line, PLZF is predominantly associated with transcribed genes. Additionally, we identify a new association between PLZF and the histone methyltransferase, EZH2 at the genomic level. We find that co-occupancy of PLZF and EZH2 on chromatin at PLZF target genes is not associated with SUZ12 or trimethylated lysine 27 of histone H3 (H3K27me3) but with the active histone mark H3K4me3 and active transcription. Removal of EZH2 leads to an increase of PLZF binding and increased gene expression. Our results suggest a new role of EZH2 in restricting PLZF positive transcriptional activity independently of its canonical PRC2 activity.
Collapse
Affiliation(s)
- Myriam Koubi
- Epigenetic Factors in Normal and Malignant Hematopoiesis, Aix Marseille Université, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, 13273 Marseille Cedex 9, France
| | - Mathilde Poplineau
- Epigenetic Factors in Normal and Malignant Hematopoiesis, Aix Marseille Université, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, 13273 Marseille Cedex 9, France
| | - Julien Vernerey
- Epigenetic Factors in Normal and Malignant Hematopoiesis, Aix Marseille Université, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, 13273 Marseille Cedex 9, France
| | - Lia N'Guyen
- Epigenetic Factors in Normal and Malignant Hematopoiesis, Aix Marseille Université, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, 13273 Marseille Cedex 9, France
| | - Guillaume Tiberi
- Epigenetic Factors in Normal and Malignant Hematopoiesis, Aix Marseille Université, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, 13273 Marseille Cedex 9, France
| | - Sylvain Garciaz
- Epigenetic Factors in Normal and Malignant Hematopoiesis, Aix Marseille Université, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, 13273 Marseille Cedex 9, France
| | - Abdessamad El-Kaoutari
- Epigenetic Factors in Normal and Malignant Hematopoiesis, Aix Marseille Université, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, 13273 Marseille Cedex 9, France
| | - Muhammad A Maqbool
- Institut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS, 34293 Montpellier, Cedex 5, France
| | - Jean-Christophe Andrau
- Institut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS, 34293 Montpellier, Cedex 5, France
| | - Christel Guillouf
- Gustave Roussy, Université Paris-Saclay, Inserm U1170, CNRS Villejuif, France
| | - Andrew J Saurin
- Aix Marseille Université, CNRS, IBDM, UMR 7288, 13288 Marseille, Cedex 9, France
| | - Estelle Duprez
- Epigenetic Factors in Normal and Malignant Hematopoiesis, Aix Marseille Université, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, 13273 Marseille Cedex 9, France
| |
Collapse
|
19
|
Garciaz S, Loschi M, De Masson A, Biard L, Mercier M, Tomowiak C, Delage J, Labussiere-Wallet H, Sibon D, Cassuto O, Borel C, Cornillon J, Nimubona S, Charbonnier A, Brice P, Socié G, Bouabdallah R, de Latour RP, de Fontbrune FS. Brentuximab vedotin as a bridge to allogeneic stem-cell transplantation for refractory or relapsing patients with CD30 positive anaplastic or T-cell non-Hodgkin lymphomas: a study on behalf of the SFGM-TC. Leuk Lymphoma 2019; 60:2802-2805. [DOI: 10.1080/10428194.2019.1599112] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Affiliation(s)
- Sylvain Garciaz
- Department of Hematology, Institut Paoli-Calmettes, Marseille, France
| | - Mickael Loschi
- Hematology service, Centre Hospitalier Universitaire, Nice, France
| | - Adèle De Masson
- Dermatology service, INSERM U976, H˛pital Saint Louis APHP, Paris, France
| | - Lucie Biard
- Biostatistics and medical information unit, INSERM U1153 ECSTRA team - H˛pital Saint-Louis, Paris, France
| | | | - Cécile Tomowiak
- Onco-hematology and cellular therapy service, CHU Poitiers, Poitiers, France
| | - Jeremy Delage
- Hematology service, CHU Lapeyronie, Montpellier, France
| | | | - David Sibon
- Hematology service, H˛pital Necker, APHP, Paris, France
| | - Ophélie Cassuto
- Hematology service, Centre Hospitalier Universitaire, Nice, France
| | - Cécile Borel
- Hematology service, CHU Purpan, Toulouse, France
| | - Jérome Cornillon
- Hematology service, Institut de cancérologie Lucien Neuwirth, Saint-Etienne, France
| | | | | | - Pauline Brice
- Hemato-oncology service, H˛pital Saint-Louis, Paris, France
| | - Gérard Socié
- Hemato-oncology service, H˛pital Saint-Louis, Paris, France
| | - Reda Bouabdallah
- Department of Hematology, Institut Paoli-Calmettes, Marseille, France
| | - Régis Peffault de Latour
- Hematology and stem-cell transplantation unit, H˛pital Saint-Louis, Université Paris Diderot, Paris, France
| | - Flore Sicre de Fontbrune
- Hematology and stem-cell transplantation unit, H˛pital Saint-Louis, Université Paris Diderot, Paris, France
| |
Collapse
|
20
|
Rossi C, Gilhodes J, Maerevoet M, Herbaux C, Morschhauser F, Brice P, Garciaz S, Borel C, Ysebaert L, Obéric L, Lazarovici J, Deau B, Dupuis J, Chauchet A, Abraham J, Bijou F, Stamatoullas-Bastard A, Malfuson JV, Golfier C, Laurent C, Pericart S, Traverse-Glehen A, Kanoun S, Filleron T, Casasnovas RO, Ghesquières H. Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers. Am J Hematol 2018; 93:1042-1049. [PMID: 29884994 DOI: 10.1002/ajh.25154] [Citation(s) in RCA: 67] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2018] [Revised: 05/11/2018] [Accepted: 05/20/2018] [Indexed: 12/13/2022]
Abstract
Anti-PD-1 therapy provides high response rates in Hodgkin lymphoma (HL) patients who have relapsed or are refractory (R/R) to autologous stem cell transplantation (ASCT) and brentuximab vedotin (BV), but median progression free survival (PFS) is only one year. The efficacy of treatment following anti-PD-1 is not well known. We retrospectively investigated the efficacy of salvage therapies for unsatisfactory response to anti-PD-1 therapy, assessed by PET-CT according to the Lugano criteria, in 30 R/R HL patients. Patients were highly pre-treated before anti-PD-1 (70% received ASCT and 93% BV). Unsatisfactory responses to anti-PD1 therapy were progressive disease (PD) (n=24) and partial response (PR) (n=6). For the 24 PD patients, median anti-PD-1 related PFS was 7.5 months (95%CI, 5.7-11.6); 17 received subsequent CT alone (Group 1) and 7 received CT in addition to anti-PD-1 (Group 2). 16/24 patients (67%) obtained an objective response. In the 15 patients treated with the same CT, twelve obtained PR or complete response (CR). In Group 1, there were 7 CR (41%), 3 PR (18%), and 7 PD (41%). In Group 2, there were 4 CR (57%), 2 PR (29%), and 1 SD (14%). No unexpected toxicity was observed. Six patients who achieved response proceeded to allogeneic SCT. With a median follow-up of 12.1 months (7-14.7), the median PFS following the initiation of CT was 11 months (95%CI, 6.3; not reached) and the median of overall survival was not reached. These observations in highly pre-treated HL patients suggest that anti-PD-1 therapy might re-sensitize tumor cells to CT. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Cédric Rossi
- Cancer Research Centre of Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, France
- Department of Hematology, Dijon University Hospital, Dijon, France
| | - Julia Gilhodes
- Clinical trials office, Institut universitaire du cancer Toulouse- Oncopole, Toulouse, France
| | | | - Charles Herbaux
- Department of Hematology, Unité GRITA, CHRU Claude Huriez, Lille, France
| | | | - Pauline Brice
- Department of Hematology, CHU Paris-GH St-Louis Lariboisière F-Widal - Hôpital Saint-Louis, Paris, France
| | - Sylvain Garciaz
- Department of Hematology, Institut Paoli-Calmettes, Marseille, France
| | - Cécile Borel
- Department of Hematology, Institut universitaire du cancer Toulouse- Oncopole, Toulouse, France
| | - Loïc Ysebaert
- Department of Hematology, Institut universitaire du cancer Toulouse- Oncopole, Toulouse, France
| | - Lucie Obéric
- Department of Hematology, Institut universitaire du cancer Toulouse- Oncopole, Toulouse, France
| | - Julien Lazarovici
- Department of Hematology, Institut Gustave-Roussy, Villejuif, France
| | | | - Jehan Dupuis
- Department of Hematology, CHU Henri Mondor, Créteil, France
| | | | - Julie Abraham
- Department of Hematology, CHU Limoges, Limoges, France
| | - Fontanet Bijou
- Department of Hematology, Institut Bergonié, Bordeaux, France
| | | | - Jean-Valère Malfuson
- Department of Hematology, hôpital d'instruction des armées Percy, Clamart, France
| | - Camille Golfier
- Department of Hematology, Dijon University Hospital, Dijon, France
| | - Camille Laurent
- Anatomy-pathology Department, Institut universitaire du cancer Toulouse-Oncopole, Toulouse, France
| | - Sarah Pericart
- Anatomy-pathology Department, Institut universitaire du cancer Toulouse-Oncopole, Toulouse, France
| | | | - Salim Kanoun
- Nuclear Medecine Unit, Institut universitaire du cancer Toulouse-Oncopole, Toulouse, France
| | - Thomas Filleron
- Clinical trials office, Institut universitaire du cancer Toulouse- Oncopole, Toulouse, France
| | - René-Olivier Casasnovas
- Department of Hematology, Dijon University Hospital, Dijon, France
- INSERM UMR 1231 CHU Dijon, France
| | - Hervé Ghesquières
- Department of Hematology, Centre Hospitalier Lyon Sud, Pierre-Bénite, France
| |
Collapse
|
21
|
Chantepie SP, Garciaz S, Tchernonog E, Peyrade F, Larcher M, Diouf M, Fornecker L, Houot R, Gastinne T, Soussain C, Malak S, Lemal R, Delette C, Ibrahim A, Gac A, Reboursière E, Vilque J, Bekadja M, Casasnovas R, Gressin R, Guidez S, Coso D, Herbaux C, Yakoub‐Agha I, Bouabdallah K, Durot E, Damaj G. Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers. Am J Hematol 2018; 93:729-735. [PMID: 29473209 DOI: 10.1002/ajh.25077] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2017] [Revised: 01/28/2018] [Accepted: 02/21/2018] [Indexed: 11/06/2022]
Abstract
Carmustine shortage has led to an increase use of alternative conditioning regimens prior to autologous stem cell transplantation for the treatment of lymphoma, including Bendamustine-based (BeEAM). The aim of this study was to evaluate the safety of the BeEAM regimen in a large cohort of patients. A total of 474 patients with a median age of 56 years were analyzed. The majority of patients had diffuse large B-cell lymphoma (43.5%). Bendamustine was administered at a median dose of 197 mg/m2 /day (50-250) on days-7 and -6. The observed grade 1-4 toxicities included mucositis (83.5%), gastroenteritis (53%), skin toxicity (34%), colitis (29%), liver toxicity (19%), pneumonitis (5%), and cardiac rhythm disorders (4%). Nonrelapse mortality (NRM) was reported in 3.3% of patients. Acute renal failure (ARF) was reported in 132 cases (27.9%) (G ≥2; 12.3%). Organ toxicities and death were more frequent in patients with post conditioning renal failure. In a multivariate analysis, pretransplant chronic renal failure, bendamustine dose >160 mg/m2 and age were independent prognostic factors for ARF. Pretransplant chronic renal failure, hyperhydration volume, duration of hyperhydration, and etoposide dose were predictive factors of NRM. A simple, four-point scoring system can stratify patients by levels of risk for ARF and may allow for a reduction in the bendamustine dose to avoid toxicity. Drugs shortage may have dangerous consequences. Prospective, comparative studies are needed to confirm the toxicity/efficacy extents from this conditioning regimen compared to other types of high dose therapy.
Collapse
Affiliation(s)
| | | | | | | | | | - Momar Diouf
- Clinical Research DepartmentAmiens University hospitalAmiensEA4666 France
| | | | - Roch Houot
- Hematology, University hospitalRennes France
| | - Thomas Gastinne
- Department of HematologyNantes University HospitalNantes France
| | - Carole Soussain
- Department of HematologyCurie Institute, Hôpital René HugueninSaint‐Cloud France
| | - Sandra Malak
- Department of HematologyCurie Institute, Hôpital René HugueninSaint‐Cloud France
| | - Richard Lemal
- Service d'hématologie clinique adulte et de thérapie cellulaire, CHU ESTAING, EA 7453 CHELTER, Université Clermont Auvergne CIC‐501Clermont‐Ferrand France
| | | | | | | | | | - Jean‐Pierre Vilque
- Institut d'Hématologie de Basse‐Normandie, Centre François BaclesseCaen France
| | - Mohamed‐Amine Bekadja
- Hematology and Cell TherapyEtablissement Hospitalier Universitaire (EHU) 1st NovemberOran Algeria
| | | | | | - Stéphanie Guidez
- Oncologie hématologique et thérapie cellulaire, CHU PoitiersPoitiers France
| | - Diane Coso
- Department of HematologyInstitut Paoli CalmettesMarseille
| | - Charles Herbaux
- Hematology, Hôpital HURIEZ UAM allogreffe de CSH, CHRULille France
| | | | | | - Eric Durot
- Department of HematologyCentre Hospitalier UniversitaireReims Cedex FRA
| | - Gandhi Damaj
- Institut d'Hématologie de Basse‐Normandie, CHUCaen France
- Microenvironnement Cellulaire et Pathologies, Normandie Univ, UnicaenMILPAT Caen14000 France
| |
Collapse
|
22
|
Garciaz S, Oziel-Taieb S, Dermeche S, Ries P, Vessaud J, Raoul JL. Acute Immune Hematological Complication of Oxaliplatin. A Series of 3 Cases. Tumori Journal 2018. [DOI: 10.1177/1430.15831] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Affiliation(s)
- Sylvain Garciaz
- Department of Medical Oncology, Paoli-Calmettes Institute, Marseille, France
| | | | - Slimane Dermeche
- Department of Medical Oncology, Paoli-Calmettes Institute, Marseille, France
| | - Pauline Ries
- Department of Medical Oncology, Paoli-Calmettes Institute, Marseille, France
| | - Julie Vessaud
- Department of Medical Oncology, Paoli-Calmettes Institute, Marseille, France
| | - Jean-Luc Raoul
- Department of Medical Oncology, Paoli-Calmettes Institute, Marseille, France
| |
Collapse
|
23
|
Garciaz S, Coso D, Brice P, Bouabdallah R. [Hodgkin and non-Hodgkin lymphoma of adolescents and young adults]. Bull Cancer 2016; 103:1035-1049. [PMID: 27866679 DOI: 10.1016/j.bulcan.2016.10.011] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2016] [Revised: 10/07/2016] [Accepted: 10/07/2016] [Indexed: 12/18/2022]
Abstract
Lymphoma is one of the most frequent cancers in adolescent and young adults. Hodgkin Lymphoma is curable in more than 90% of cases. Recent pediatric and adults protocols aimed to decrease long term toxicities (mostly gonadic and cardiovascular) and secondary malignancies, reducing the use of alkylating agents and limiting radiation fields. Risk-adapted strategies, using positron emission tomography staging, are about to become a standard, both in adult and pediatric protocols. These approaches allow obtaining excellent results in adolescents with Hodgkin lymphoma. On the other hand, treatment of adolescents with diffuse large B-cell lymphoma raises some questions. Even through children have good outcomes when treated with risk-adapted strategies, adolescents who are between 15 and 18 years old seem to experience poorer survivals, whereas patients older than 18 years old have globally the same outcome than older adults. This category of patient needs a particular care, based on a tight coordination between adults and pediatric oncologists. Primary mediastinal lymphomas, a subtype of BLDCL frequent in young adult population, exhibits poorer outcomes in children or young adolescent population than in older ones. Taking together, B-cell lymphoma benefited from recent advances in immunotherapy (in particular with the extended utilization of rituximab) and metabolic response-adapted strategies. In conclusion, adolescent and young adult's lymphomas are very curable diseases but require a personalized management in onco-hematological units.
Collapse
Affiliation(s)
- Sylvain Garciaz
- Institut Paoli-Calmettes, département d'hématologie, 232, boulevard Sainte-Marguerite, 13009 Marseille, France.
| | - Diane Coso
- Institut Paoli-Calmettes, département d'hématologie, 232, boulevard Sainte-Marguerite, 13009 Marseille, France
| | - Pauline Brice
- Hôpital Saint-Louis, service d'hémato-oncologie, 1, avenue Claude-Vellefaux, 75010 Paris, France
| | - Réda Bouabdallah
- Institut Paoli-Calmettes, département d'hématologie, 232, boulevard Sainte-Marguerite, 13009 Marseille, France
| |
Collapse
|
24
|
Abstract
INTRODUCTION Although the combination of an anti-CD20 monoclonal antibody and chemotherapy has widely improved survival of patients with B-cell lymphoma, the disease still relapses. A better understanding of the biology of lymphomas has highlighted the role of the cell of origin in response to treatment and outcome. Lenalidomide represents an attractive therapeutic option due to its original mechanism of action. AREAS COVERED In this review, the authors describe the pharmacological properties of lenalidomide, and the rational for its use in B-cell lymphomas; focusing on diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). They discuss the mechanism of action of the drug and its current and future clinical development. They also review the current data in relapsed/refractory situations as well as in first-line treatment. EXPERT OPINION Lenalidomide is an oral non-chemotherapy immunomodulatory agent with an acceptable toxicity profile and manageable side-effects. Efficacy has widely been demonstrated, especially in MCL, FL and non-Germinal Center DLBCL patients. Further studies are now warranted to better define the strategy for the use of lenalidomide in B-NHL patients, and clarify which subgroup of patients will really benefit of lenalidomide as part of first-line treatment or in a relapsed/refractory setting.
Collapse
Affiliation(s)
- Sylvain Garciaz
- a Department of Hematology, Institut Paoli-Calmettes , Université de la Méditerranée , Marseille , France
| | - Diane Coso
- a Department of Hematology, Institut Paoli-Calmettes , Université de la Méditerranée , Marseille , France
| | | | - Réda Bouabdallah
- a Department of Hematology, Institut Paoli-Calmettes , Université de la Méditerranée , Marseille , France
| |
Collapse
|
25
|
Restivo L, Apostolidis T, Bouhnik AD, Garciaz S, Aurran T, Julian-Reynier C. Patients' Non-Medical Characteristics Contribute to Collective Medical Decision-Making at Multidisciplinary Oncological Team Meetings. PLoS One 2016; 11:e0154969. [PMID: 27167521 PMCID: PMC4864423 DOI: 10.1371/journal.pone.0154969] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2015] [Accepted: 04/21/2016] [Indexed: 12/24/2022] Open
Abstract
Background The contribution of patients’ non-medical characteristics to individual physicians’ decision-making has attracted considerable attention, but little information is available on this topic in the context of collective decision-making. Medical decision-making at cancer centres is currently carried out using a collective approach, at MultiDisciplinary Team (MDT) meetings. The aim of this study was to determine how patients’ non-medical characteristics are presented at MDT meetings and how this information may affect the team’s final medical decisions. Design Observations were conducted at a French Cancer Centre during MDT meetings at which non-standard cases involving some uncertainty were discussed from March to May 2014. Physicians’ verbal statements and predefined contextual parameters were collected with a non-participant observational approach. Non numerical data collected in the form of open notes were then coded for quantitative analysis. Univariate and multivariate statistical analyses were performed. Results In the final sample of patients’ records included and discussed (N = 290), non-medical characteristics were mentioned in 32.8% (n = 95) of the cases. These characteristics corresponded to demographics in 22.8% (n = 66) of the cases, psychological data in 11.7% (n = 34), and relational data in 6.2% (n = 18). The patient’s age and his/her “likeability” were the most frequently mentioned characteristics. In 17.9% of the cases discussed, the final decision was deferred: this outcome was positively associated with the patients’ non-medical characteristics and with uncertainty about the outcome of the therapeutic options available. Limitations The design of the study made it difficult to draw definite cause-and-effect conclusions. Conclusion The Social Representations approach suggests that patients’ non-medical characteristics constitute a kind of tacit professional knowledge that may be frequently mobilised in physicians’ everyday professional practice. The links observed between patients’ attributes and the medical decisions made at these meetings show that these attributes should be taken into account in order to understand how medical decisions are reached in difficult situations of this kind.
Collapse
Affiliation(s)
- Léa Restivo
- Aix Marseille Université, Laboratoire de Psychologie Sociale EA 849, Aix en Provence, France.,INSERM, UMR912 (SESSTIM), Marseille, France.,Aix Marseille Université, UMR_S912, IRD, Marseille, France
| | - Thémis Apostolidis
- Aix Marseille Université, Laboratoire de Psychologie Sociale EA 849, Aix en Provence, France
| | - Anne-Déborah Bouhnik
- INSERM, UMR912 (SESSTIM), Marseille, France.,Aix Marseille Université, UMR_S912, IRD, Marseille, France
| | | | | | - Claire Julian-Reynier
- INSERM, UMR912 (SESSTIM), Marseille, France.,Aix Marseille Université, UMR_S912, IRD, Marseille, France.,Institut Paoli-Calmettes, Marseille, France
| |
Collapse
|
26
|
Garciaz S, Harel S, Amorim S, Bouabdallah R, Thieblemont C, Brice P. Rituximab-ABV(D) for patients with Nodular lymphocyte predominant Hodgkin lymphoma ineligible for radiation therapy. Br J Haematol 2015; 175:735-737. [DOI: 10.1111/bjh.13879] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Sylvain Garciaz
- Department of Haematology; Institut Paoli-Calmettes; Marseille France
| | - Stephanie Harel
- Department of Haematology; APHP; Hôpital Saint-Louis; Paris France
| | - Sandy Amorim
- Department of Haematology; APHP; Hôpital Saint-Louis; Paris France
| | - Réda Bouabdallah
- Department of Haematology; Institut Paoli-Calmettes; Marseille France
| | | | - Pauline Brice
- Department of Haematology; APHP; Hôpital Saint-Louis; Paris France
| |
Collapse
|
27
|
Garciaz S, Coso D, Schiano de Collela JM, Broussais F, Stoppa AM, Aurran T, Chabannon C, Helvig A, Xerri L, Blaise D, Bouabdallah R. Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity. Bone Marrow Transplant 2015; 51:319-21. [PMID: 26524266 DOI: 10.1038/bmt.2015.257] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
- S Garciaz
- Cancer Center Institut J. Paoli-I. Calmettes-Université de la Méditerranée, Marseille, France
| | - D Coso
- Cancer Center Institut J. Paoli-I. Calmettes-Université de la Méditerranée, Marseille, France
| | - J-M Schiano de Collela
- Cancer Center Institut J. Paoli-I. Calmettes-Université de la Méditerranée, Marseille, France
| | - F Broussais
- Cancer Center Institut J. Paoli-I. Calmettes-Université de la Méditerranée, Marseille, France
| | - A-M Stoppa
- Cancer Center Institut J. Paoli-I. Calmettes-Université de la Méditerranée, Marseille, France
| | - T Aurran
- Cancer Center Institut J. Paoli-I. Calmettes-Université de la Méditerranée, Marseille, France
| | - C Chabannon
- Cancer Center Institut J. Paoli-I. Calmettes-Université de la Méditerranée, Marseille, France
| | - A Helvig
- Cancer Center Institut J. Paoli-I. Calmettes-Université de la Méditerranée, Marseille, France
| | - L Xerri
- Cancer Center Institut J. Paoli-I. Calmettes-Université de la Méditerranée, Marseille, France
| | - D Blaise
- Cancer Center Institut J. Paoli-I. Calmettes-Université de la Méditerranée, Marseille, France
| | - R Bouabdallah
- Cancer Center Institut J. Paoli-I. Calmettes-Université de la Méditerranée, Marseille, France
| |
Collapse
|
28
|
Crocchiolo R, Castagna L, Garciaz S, Fürst S, El Cheikh J, Sarina B, Bramanti S, Granata A, Vai A, Harbi S, Morabito L, Mohty B, Giordano L, Devillier R, Coso D, Balzarotti M, Chabannon C, Carlo-Stella C, Santoro A, Bouabdallah R, Blaise D. Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients. Haematologica 2015. [PMID: 26206800 DOI: 10.3324/haematol.2015.129452] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Affiliation(s)
| | - Luca Castagna
- Hematology Unit, Humanitas Clinical and Research Center, Rozzano, Italy
| | - Sylvain Garciaz
- Hematology Department, Institut Paoli-Calmettes, Marseille, France
| | - Sabine Fürst
- Hematology Department, Institut Paoli-Calmettes, Marseille, France
| | - Jean El Cheikh
- Hematology Department, Institut Paoli-Calmettes, Marseille, France
| | - Barbara Sarina
- Hematology Unit, Humanitas Clinical and Research Center, Rozzano, Italy
| | - Stefania Bramanti
- Hematology Unit, Humanitas Clinical and Research Center, Rozzano, Italy
| | - Angela Granata
- Hematology Department, Institut Paoli-Calmettes, Marseille, France
| | - Andrea Vai
- Hematology Unit, Humanitas Clinical and Research Center, Rozzano, Italy
| | - Samia Harbi
- Hematology Department, Institut Paoli-Calmettes, Marseille, France
| | - Lucio Morabito
- Hematology Unit, Humanitas Clinical and Research Center, Rozzano, Italy
| | - Bilal Mohty
- Hematology Department, Institut Paoli-Calmettes, Marseille, France
| | - Laura Giordano
- Biostatistic Unit, Humanitas Clinical and Research Center, Rozzano, Italy
| | | | - Diane Coso
- Hematology Department, Institut Paoli-Calmettes, Marseille, France
| | - Monica Balzarotti
- Hematology Unit, Humanitas Clinical and Research Center, Rozzano, Italy
| | | | | | - Armando Santoro
- Hematology Unit, Humanitas Clinical and Research Center, Rozzano, Italy
| | - Reda Bouabdallah
- Hematology Department, Institut Paoli-Calmettes, Marseille, France
| | - Didier Blaise
- Hematology Department, Institut Paoli-Calmettes, Marseille, France
| |
Collapse
|
29
|
Garciaz S, Castagna L, Bouabdallah R, Fürst S, Bramanti S, Coso D, Crocchiolo R, El-Cheikh J, Broussais F, Chabannon C, Santoro A, Blaise D. Erratum: Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not available. Bone Marrow Transplant 2015; 50:880. [DOI: 10.1038/bmt.2015.79] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
30
|
Garciaz S, Castagna L, Bouabdallah R, Fürst S, Bramanti S, Coso D, Crocchiolo R, El-Cheikh J, Broussais F, Chabannon C, Santoro A, Blaise D. Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not available. Bone Marrow Transplant 2015; 50:865-7. [PMID: 25730187 DOI: 10.1038/bmt.2015.22] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Affiliation(s)
- S Garciaz
- Department of Hematology, Institut Paoli Calmettes, Marseille, France
| | - L Castagna
- Department of Hematology, Humanitas Cancer Center, Rozzano, Italy
| | - R Bouabdallah
- Department of Hematology, Institut Paoli Calmettes, Marseille, France
| | - S Fürst
- Department of Hematology, Institut Paoli Calmettes, Marseille, France
| | - S Bramanti
- Department of Hematology, Humanitas Cancer Center, Rozzano, Italy
| | - D Coso
- Department of Hematology, Institut Paoli Calmettes, Marseille, France
| | - R Crocchiolo
- Department of Hematology, Humanitas Cancer Center, Rozzano, Italy
| | - J El-Cheikh
- Department of Hematology, Institut Paoli Calmettes, Marseille, France
| | - F Broussais
- Department of Hematology, Institut Paoli Calmettes, Marseille, France
| | - C Chabannon
- Department of Hematology, Institut Paoli Calmettes, Marseille, France
| | - A Santoro
- Department of Hematology, Humanitas Cancer Center, Rozzano, Italy
| | - D Blaise
- Department of Hematology, Institut Paoli Calmettes, Marseille, France
| |
Collapse
|
31
|
Mamessier E, Drevet C, Broussais-Guillaumot F, Mollichella ML, Garciaz S, Roulland S, Benchetrit M, Nadel B, Xerri L. Contiguous follicular lymphoma and follicular lymphoma in situ harboring N-glycosylated sites. Haematologica 2014; 100:e155-7. [PMID: 25527563 DOI: 10.3324/haematol.2014.115782] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Affiliation(s)
- Emilie Mamessier
- INSERM U1104, Marseille Centre d'Immunologie de Marseille Luminy, Université de la Méditerranée, Marseille CNRS UMR7280, Marseille
| | - Charlotte Drevet
- INSERM U1104, Marseille Centre d'Immunologie de Marseille Luminy, Université de la Méditerranée, Marseille CNRS UMR7280, Marseille
| | | | - Marie-Laure Mollichella
- INSERM U1104, Marseille Centre d'Immunologie de Marseille Luminy, Université de la Méditerranée, Marseille CNRS UMR7280, Marseille
| | - Sylvain Garciaz
- INSERM U1104, Marseille Centre d'Immunologie de Marseille Luminy, Université de la Méditerranée, Marseille CNRS UMR7280, Marseille
| | - Sandrine Roulland
- INSERM U1104, Marseille Centre d'Immunologie de Marseille Luminy, Université de la Méditerranée, Marseille CNRS UMR7280, Marseille
| | - Maxime Benchetrit
- Service d'Onco-hématologie adulte, Institut Paoli Calmettes, Marseille
| | - Bertrand Nadel
- INSERM U1104, Marseille Centre d'Immunologie de Marseille Luminy, Université de la Méditerranée, Marseille CNRS UMR7280, Marseille
| | | |
Collapse
|
32
|
Garciaz S, Castagna L, Furst S, Bramenti S, El Cheikh J, Crocchiolo R, Coso D, Esterni B, Schiano JM, Sarina B, Calmels B, Granata A, Devillier R, Harbi S, Bouabdallah R, Santoro A, Blaise D. Haploidentical stem cell transplantation (Haplo-HSCT) with nonmyeloablative conditioning regimen (NMAC) and postinfusion cyclophosphamide in advanced non-Hodgkin lymphoma (NHL) patients. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.7039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | | | | | | | | | - Diane Coso
- Institut Paoli Calmettes, Marseille, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Garciaz S, Castagna L, El Cheikh J, Bramanti S, Furst S, Crocchiolo R, Coso D, Esterni B, Broussais F, Sarina B, Lemarie C, Granata A, Devillier R, Harbi S, Bouabdallah R, Santoro A, Blaise D. Allogeneic hematopoietic stem cell transplantation in a cohort of 314 advanced lymphoma patients. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.8568] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | | | | | | | | | - Diane Coso
- Institut Paoli Calmettes, Marseille, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Garciaz S, Oziel-Taieb S, Dermeche S, Ries P, Vessaud J, Raoul JL. Acute immune hematological complication of oxaliplatin. A series of 3 cases. Tumori 2014; 100:e17-9. [PMID: 24675502 DOI: 10.1700/1430.15831] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
We report a series of three cases of oxaliplatin-related hematological immune reactions. Two patients developed acute immune hemolytic anemia and the third patient had severe thrombocytopenia. One patient had minor undiagnosed hemolysis after the previous chemotherapy cycle and two of our three patients had minor allergic signs just before the hemolysis. Fifteen cases of immune hemolytic anemia have been reported in the literature, of which only the first was fatal. One case of hemolytic uremic syndrome has been described. Anemia in cancer patients is not always related to myelosuppression and hemolytic anemia can be a severe side effect of oxaliplatin administration.
Collapse
|
35
|
Fouquet G, Hebraud B, Garciaz S, Stoppa AM, Roussel M, Caillot D, Chrétien ML, Arnulf B, Szalat R, Garderet L, Benajiba L, Pegourie B, Regny C, Royer B, Caulier A, Touzeau C, Tessoulin B, Fermand JP, Facon T, Attal M, Loiseau HA, Moreau P, Leleu X. Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation. J Cancer 2014; 5:248-52. [PMID: 24665349 PMCID: PMC3963082 DOI: 10.7150/jca.8541] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2013] [Accepted: 02/18/2014] [Indexed: 12/22/2022] Open
Abstract
The impact of consolidation on response rates and PFS has recently been demonstrated after induction and autotransplantation upfront in Multiple Myeloma (MM). We further showed that patients in ≥VGPR following the intensification procedure benefited most from consolidation. Question remains as to the benefit of consolidation for patients in PR at completion of induction - feature of partial resistance to the induction regimen. We collected data from 54 newly diagnosed MM treated with VTd-auto-VTd regimen that reached only PR at completion of the induction procedure. Overall, 37 patients (68%) improved depth of response (≥VGPR) at completion of consolidation, including 35% that reached CR and 38% solely related to consolidation. Of patients that remained on PR or improved depth of response after ASCT, 26% and 38% further responded to consolidation, respectively. With a median follow-up of 36 months, improved depth of response translated into lower relapse rate compared with patients remaining in PR, 19% vs. 36%. This difference was more striking in patients that reached CR vs. others, 8% and 38%, respectively (p=0.039). The median TTP was prolonged in patients that improved depth of response after consolidation (p=0.012), with a 3-year TTP of 87% vs. 18% otherwise. In multivariate analysis, lack of improved depth of response to consolidation independently predicted shorten median TTP [OR=4.4, 95%CI=1-21; p=0.039], with elevated LDH and beta2m, and adverse FISH. This study shows that VTd consolidation should be recommended to patients solely on PR at completion of induction with VTd, feature of lower sensitivity to VTd.
Collapse
|
36
|
Coso D, Garciaz S, Esterni B, Broussais-Guillaumot F, Ivanov V, Aurran-Schleinitz T, Schiano JM, Stoppa AM, Chetaille B, Blaise D, Vey N, Bouabdallah R. Large B-cell lymphomas in adolescents and young adults in comparison to adult patients: a matched-control analysis in 55 patients. Leuk Lymphoma 2014; 55:1849-53. [DOI: 10.3109/10428194.2013.858814] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
37
|
Garciaz S, Coso D, Peyrade F, Fürst S, Duran S, Chetaille B, Brenot-Rossi I, Devillier R, Granata A, Blaise D, Bouabdallah R. Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma. Hematol Oncol 2013; 32:187-91. [PMID: 24301099 DOI: 10.1002/hon.2119] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2013] [Revised: 09/30/2013] [Accepted: 10/30/2013] [Indexed: 11/09/2022]
Abstract
Patients with relapsed or refractory Hodgkin lymphoma (RR-HL) have poor outcomes. Brentuximab vedotin (BV), an antibody-drug conjugate comprising an anti-CD30 antibody conjugated to the potent anti-microtubule agent, monomethyl auristatin E, induces high tumour responses with moderate adverse effects. In a retrospective study, we describe objective response rates and subsequent allogeneic stem cell transplantation (allo-SCT) in patients with RR-HL treated by BV in a named patient program in two French institutions. Twenty-four adult patients with histologically proven CD30(+) RR-HL treated with BV were included from July 2009 to November 2012. Response to BV treatment was evaluated after four cycles. Eleven patients were in complete response (45.8%), while five patients were in partial response (20.8%), with an overall response rate of 66.6%. Eight patients failed to respond to BV (33.3%). All of the responding patients could receive consolidation treatment after BV: three patients underwent autologous stem cell transplantation (auto-SCT), three patients received a tandem auto-SCT/allo-SCT, nine patients received allo-SCT and one patient was treated with donor lymphocyte infusion. We found no treatment-related mortality at day 100 among the 12 patients who underwent BV following by allogeneic transplantation. With a median follow-up of 20 months (range 10.5-43.2), none of them relapsed or died. BV followed by allo-SCT represents an effective salvage regimen in patients with RR-HL.
Collapse
Affiliation(s)
- Sylvain Garciaz
- Department of Hematology, Institut Paoli-Calmettes-Université de la Méditerranée, Marseille, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
De Masson A, Beylot-Barry M, Bouaziz JD, Aubin F, Garciaz S, d’Incan M, Dereure O, Dalle S, Dompmartin A, Suarez F, Adamski H, Battistella M, Rivet J, Vignon-Pennamen MD, Brice P, François S, Lissandre S, Turlure P, Hainaut E, Brissot E, Dulery R, Ravinet A, Servais S, Ingen-Housz-Oro S, Joly P, Socié G, Bagot M. Allogreffe de cellules souches hématopoïétiques dans 37 cas de mycosis fongoïde transformé et autres lymphomes T cutanés primitifs de stade avancé. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
39
|
de Masson A, Beylot-Barry M, Bouaziz JD, Peffault de Latour R, Aubin F, Garciaz S, d'Incan M, Dereure O, Dalle S, Dompmartin A, Suarez F, Battistella M, Vignon-Pennamen MD, Rivet J, Adamski H, Brice P, François S, Lissandre S, Turlure P, Wierzbicka-Hainaut E, Brissot E, Dulery R, Servais S, Ravinet A, Tabrizi R, Ingen-Housz-Oro S, Joly P, Socié G, Bagot M. Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas. Haematologica 2013; 99:527-34. [PMID: 24213148 DOI: 10.3324/haematol.2013.098145] [Citation(s) in RCA: 60] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
The treatment of advanced stage primary cutaneous T-cell lymphomas remains challenging. In particular, large-cell transformation of mycosis fungoides is associated with a median overall survival of two years for all stages taken together. Little is known regarding allogeneic hematopoietic stem cell transplantation in this context. We performed a multicenter retrospective analysis of 37 cases of advanced stage primary cutaneous T-cell lymphomas treated with allogeneic stem cell transplantation, including 20 (54%) transformed mycosis fungoides. Twenty-four patients (65%) had stage IV disease (for mycosis fungoides and Sézary syndrome) or disseminated nodal or visceral involvement (for non-epidermotropic primary cutaneous T-cell lymphomas). After a median follow up of 29 months, 19 patients experienced a relapse, leading to a 2-year cumulative incidence of relapse of 56% (95%CI: 0.38-0.74). Estimated 2-year overall survival was 57% (95%CI: 0.41-0.77) and progression-free survival 31% (95%CI: 0.19-0.53). Six of 19 patients with a post-transplant relapse achieved a subsequent complete remission after salvage therapy, with a median duration of 41 months. A weak residual tumor burden before transplantation was associated with increased progression-free survival (HR=0.3, 95%CI: 0.1-0.8; P=0.01). The use of antithymocyte globulin significantly reduced progression-free survival (HR=2.9, 95%CI: 1.3-6.2; P=0.01) but also transplant-related mortality (HR=10(-7), 95%CI: 4.10(-8)-2.10(-7); P<0.001) in univariate analysis. In multivariate analysis, the use of antithymocyte globulin was the only factor significantly associated with decreased progression-free survival (P=0.04). Allogeneic stem cell transplantation should be considered in advanced stage primary cutaneous T-cell lymphomas, including transformed mycosis fungoides.
Collapse
|
40
|
Garciaz S, Bouvier C, Roche PH, Salas S. Primary dediffentiated liposarcoma of the dura mater: case report. Acta Neurochir (Wien) 2012; 154:1737-8. [PMID: 22843199 DOI: 10.1007/s00701-012-1449-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2012] [Accepted: 07/06/2012] [Indexed: 11/30/2022]
|